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ABSTRACT 
Endocannabinoids (eCBs) are bioactive lipids which primarily infl uence 
synaptic communication within the nervous system. They are synthesized by 
neurons but also by microglia, especially under neuroinflammatory conditions. To 
exert their function, eCBs travel across the intercellular space. However, how eCBs 
move extracellularly remains obscure. Our recent evidence indicates that reactive 
microglia release extracellular vesicles (EVs), which may represent an ideal vehicle 
for the transport of hydrophobic eCBs. Hence, in this study we investigated 
whether microglial EVs carry eCBs and may influence neurotransmission. 
First we analyzed the eCB content of EVs and found a clear enrichment of 
N-arachidonoylethanolamine (AEA) in EVs relative to parental microglia. This 
analysis revealed higher AEA levels in EVs shed from the plasma membrane 
(microvesicles), compared to those which originate from the endocytic 
compartment (exosomes). To bioassay the activity of vesicular AEA, we used patch 
clamp analysis of miniature inhibitory post-synaptic currents (mIPSC) on rat 
hippocampal primary culture. Exposure of neurons to microvesicles (MVs) induced 
a significant decrease in mIPSC frequency,  mimicking the well-known inhibitory 
action of CB1 receptor agonists. The involvement of vesicular AEA in this 
phenomenon was inferred from the ability of the CB1 receptor antagonist 
SR141716A to block the reduction of mIPSC frequency evoked by MVs. Western 
blot analysis showed an increase in ERK phosphorylation in neurons exposed to 
MVs, which was completely inhibited by SR141716A. This indicate that CB1 
receptors activation by AEA-storing MVs translates into downstream signaling.  
Finally, the use of biotin-AEA revealed an affinity of AEA for MV 
membrane, indicating that AEA travels in association with MVs surface. Consistent 
with a surface localization of AEA, MV membranes maintain their capability to 
decrease mIPSC frequency. 
Overall, this study shows that microglial MVs carry AEA on their surface to 
stimulate CB1 receptors on target GABAergic neurons and demonstrates that 
extracellular vesicular transport of eCBs play a crucial role in the modulation of 
inhibitory transmission.  
 
 
- 5 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This abstract is  copyrighted  
© 2015 Gabrielli et al 
SpringerPlus 2015, 4(Suppl 1):L29  doi:10.1186/2193-1801-4-S1-L29, modified; 
The electronic version of this abstract is the complete one and can be found online at: 
http://www.springerplus.com/content/4/S1/L29 
This abstract is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
- 6 - 
 
ABBREVIATION LIST 
Aβ: β-amiloid 
2-AG: 2-arachidonoylglycerol 
ABDH-6: serine hydrolase α-β-hydrolase domain 6 
AC: adenylyl cyclase 
AD: Alzheimer’s disease 
AEA: anandamide, N-arachidonoylethanolamine 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AMT: AEA membrane transporter’ protein 
A-SMase: acid sphingomyelinase 
ATP: adenosine-5'-triphosphate 
Ca
++
: calcium ions 
cAMP: cyclic adenosine monophosphate 
CB1 receptors: cannabinoid type I receptors 
CNS: central nervous system 
CSF: cerebrospinal fluid 
DAPI: 4',6-diamidino-2-phenylindole 
DAG: diacylglycerol 
DIV: days in vitro 
DRG: dorsal root ganglion 
EAE: experimental autoimmune encephalomyelitis 
eCBs: endocannabinoids 
ESCRT: endosomal sorting complex responsible for transport 
ERK: extracellular signal-regulated kinase 
EVs: extracellular vesicles 
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FAAH: fatty acid amine hydrolase 
fGFP: farnesylated green fluorescent protein 
FLAT: FAAH-like AEA transporter 
GABA: γ-aminobutyric acid 
GAD: glutamic acid decarboxylase 
HD: Huntington’s disease 
ICAM: intercellular adhesion molecules 
IL-1β: interleukin-1β 
mEPSCs: miniature excitatory postsynaptic currents 
mIPSCs: miniature inhibitory postsynaptic currents 
LC-ESI-MS: liquid chromatography - electrospray ion source - mass spectrometry 
MGL: monoacyl glycerol lipase 
MHC: major histocompatibility complex 
MS: multiple sclerosis 
MVs: microvesicles 
MVE: multivesicular endosomes 
NAPE: N-arachidonoyl phosphatidylethanolamine 
NMDA:  N-methyl-D-aspartate 
OEA: N-oleoylethanolamide 
oATP: oxidized ATP 
PD: Parkinson’s disease 
P-ERK: phosphorilated ERK 
PKA: cAMP-dependent protein kinase 
PLCβ: phospholipase C β 
PLD: phospholipase D 
PS: phosphatidylserine 
KRH: Krebs-Ringer’s HEPES solution 
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S1P: sphingosine-1-phosphate 
SNAREs: Soluble NSF Attachment Protein Receptors 
Sph: Sphingosine 
TNFα: tumor necrosis factor alpha 
TRPV1: transient receptor potential vanilloid type I receptors 
TGFβ: transforming growth factor bet 
VEPs: visual evoked potentials  
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1. The synapse 
The synapse is where communication between two neurons takes place. 
Synaptic communication occurs between a presynaptic terminal and a postsynaptic 
compartment, thanks to the excitable nature of neurons, which change their 
membrane potential in response to stimuli.  In chemical synapses, when an action 
potential reaches the presynaptic terminal, it induces neurotransmitter release 
through activation of voltage-gated calcium (Ca
++
) channels and the consequent 
fusion of neurotransmitter-storing synaptic vesicles with the presynaptic 
membrane. Neurotransmitters are hence released in the synaptic cleft (the 
intercellular space between pre and postsynaptic membrane) where they interact 
with their specific receptors placed on the postsynaptic membrane, thus inducing 
opening of ion channels and the consequent alteration of membrane potential 
(Sudhof, 2004). If the sum of generated postsynaptic currents reaches a specific 
threshold value, a new action potential is elicited in the postsynaptic neuron. 
(Figure I) 
Excitatory synapses induce depolarization in the postsynaptic neurons, thus 
promoting the generation of an action potential. Instead inhibitory synapses induce 
hyperpolarization, inhibiting the generation of action potentials. In the central 
nervous system excitatory neurons typically release glutamate, while GABA is 
released from the great majority of inhibitory synapses in the brain. 
 
 
 
 
 
 
Figure I   Synaptic transmission: diagram of reactions, on the left; electrophysiological traces relative to 
reactions, on the right (Sudhof, 2004) 
 
- 11 - 
 
Synaptic transmission is a highly regulated process. The correlation between 
an action potential, the release of neurotransmitter and the postsynaptic response is 
finely modulated by a plethora of intracellular and extracellular mediators, and is 
also altered by a repeated use of the synapse, a phenomenon named synaptic 
plasticity (Sudhof, 2004).  
Glia (astrocytes, oligodendrocytes and microglial cells) play an important 
role in the regulation of neurotransmission. For many years considered as mere 
structural elements, glial cells are in fact capable of sensing signals and elaborating 
complex responses, exerting many biological functions, including the one of 
modulating synaptic transmission (Verderio and Matteoli, 2011). Astrocytes 
surround closely the synapses maintaining, supporting and modulating neuronal 
activity. Oligodendrocytes bind neuronal axons forming the myelin sheath 
(Verderio and Matteoli, 2011). Microglial cells are myeloid cells considered the 
macrophages of the brain. Beyond their immunological functions, there are growing 
evidence supporting new physiological roles for microglia and it is known that they 
release factors which alter synaptic activity (Kettenmann et al, 2013). [for a more 
detailed description of microglial functions see “Microglia” section] 
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2. The endocannabinoid system 
The mediators involved in the regulation of synaptic transmission are 
countless. Among these are the endocannabinoids (eCBs) (Castillo et al, 2012): 
fatty acid metabolites of arachidonoyl lipids (Stanton et al, 2005). 
eCBs are lipid mediators which play many different roles in 
neuromodulation. They primarily act as retrograde messengers: produced by 
neurons on demand, in response to high synaptic activity, eCBs move to 
presynaptic membrane where they activate their specific receptors, called CB1 
receptors, to inhibit neurotransmitter release (Ohno-Shosaku et al, 2001; Wilson 
and Nicoll, 2001; Katona et al, 2012) (Figure II). Retrograde eCB signaling 
happens at both excitatory and inhibitory synapses and it’s responsible for different 
forms of short- and long-term plasticity (reviewed in Benarroch, 2014; Katona and 
Freund, 2012; Castillo et al, 2012). The typical purpose of retrograde signaling is 
to control over-excitability and preserving synaptic homeostasis. Furthermore eCBs 
are very important for correct neurogenesis, synaptogenesis and circuit formation 
(Harkany et al, 2008; Berghuis et al, 2007).  
 
 
 
 
Figure II  Retrograde signaling mediated by eCBs. eCBs are synthetized mainly in the postsynaptic 
compartment of neurons on demand and move to the presynaptic terminal to activate CB1 receptors, responsible 
of inhibiting neurotransmitter release. NAPE: N-arachidonoylphosphatidilethanolamine; PLD: phospholipase D; 
CB1: type I endocannabinoid receptor. 
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CBs are produced not only by neurons, but by astrocytes and microglial 
cells too (Carrier et al, 2004; Stella, 2010; Walter et al, 2002). During 
inflammation, primary microglia release even 20-fold the amount of eCBs 
compared to neuron and astrocytes, suggesting that microglial cells may represent 
the major producers of eCBs under inflammatory conditions (Stella, 2009). These 
molecules also mediate glia-neurons interaction, being involved in 
neuromodulation, regulation of inflammatory responses and neuroprotection 
(Benarroch, 2014; Navarrete and Araque, 2008). 
eCB signaling is involved in many different brain networks, affecting 
several brain functions such as learning, memory, cognition, emotion, addiction, 
pain perception, motor control, feeding behaviors (Benarroch, 2014). 
eCB  synthesis and metabolism 
In neurons, eCBs are synthetized from membrane phospholipids of neurons, 
in response to synaptic firing: the trigger is the increase in intracellular Ca
++
 levels, 
due to depolarization-induced opening of voltage-gated Ca
++
-channels, or the 
activation of Gq/11 coupled receptor, which in turn activate specific synthetic 
enzymes. (Benarroch, 2014). Glial cells too, express the enzymes necessary for 
eCB synthesis (Carrier et al, 2004; Stella, 2010; Walter et al, 2002).  As eCBs are 
produced, they are rapidly released to exert their functions.  
 
N-arachidonoylethanolamine (anandamide, AEA) and 2-
arachidonoylglycerol (2-AG) (Figure III) are the two major eCBs. Both are present 
in the brain, with 2-AG at low micromolar and AEA at low nanomolar 
concentrations; AEA levels usually increase under inflammatory conditions 
(Nicolussi and Gertsch, 2015). They are produced and metabolized by different 
pathways. 
 
Figure III   Chemical structure of N-arachidonoylethanolamine (anandamide, AEA) and 2-arachydonoylglycerol 
(2-AG) 
anandamide (AEA) 
 
2-arachidonoylglycerol (2-AG) 
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AEA synthesis may involve different pathways but it’s primarily generated 
by phospholipase D (PLD) starting from N-arachidonoylphosphatidilethanolamine 
(NAPE), which is synthetized by N-acyltransferase enzyme. After exerting its 
function, AEA is hydrolyzed in the postsynaptic compartment by the enzyme fatty 
acid amine hydrolase (FAAH), located inside organelles such as mithocondria. 
AEA enters organelles thanks to carrier systems. 
2-AG mainly derives from phaphatidylinositol-4,5 biphosphate containing 
arachidonic acid: this lipid is hydrolyzed by phospholipase C β (PLCβ) enzyme in 
diacylglycerol (DAG), which is in turn metabolized in 2-AG by DAG lipase α. 2-
AG is inactivated by monoacyl glycerol lipase (MGL), presen t in the presynaptic 
terminal, or by serine hydrolase α-β-hydrolase domain 6 (ABDH-6), located in the 
postsynaptic compartment. (Benarroch, 2014) 
Once degraded, eCBs are incorporated into phospholipids (Nicolussi and 
Gertsch, 2015).  
eCB receptors 
Two kinds of eCB specific receptors have been described so far: CB1 
receptors (type I) and CB2 receptors (type II). 
CB1 receptors typically mediate eCB signaling in the nervous system. They 
are mainly present presynaptically on GABAergic terminals, and only marginally 
on glutamatergic and other presynaptic terminals (Kano et al, 2009; Katona and 
Freund, 2012; Katona et al, 1999). They are expressed in specific nervous system 
areas, including hippocampus, depending on cell type and developmental stage. 
eCBs may also activate postsynaptic CB1 receptors to reduce excitability. 
Relatively to glial cells, CB1 receptors are expressed in astrocytes and 
oligodendrocytes. (Benarroch, 2014) 
On the other hand, CB2 receptors are expressed mainly in immune cells, 
while their presence in neurons is controversial (Malfitano et al, 2014). Among 
glial cells, they are expressed in microglia. 
 
AEA functions as agonist also for the transient receptor potential vanilloid 
type I channel (TRPV1). 
(Benarroch, 2014; Katona et al, 2012) 
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Both CB1 and CB2 receptors are G-protein-coupled receptors, coupled to 
Gi/o. Thus, when activated, they: 
 inhibit adenylyl cyclase (AC), blocking cyclic adenosine monophosphate 
(cAMP)-protein kinase A (PKA) pathway (Gα subunit); 
 inhibit presynaptic voltage-gated Ca++ channels, included Cav2.1 (P/Q-type) 
and Cav2.2 (N-type) channels (Gβ/γ subunit); 
 activate inward rectifying and A-type potassium (K+) channels (Gβ/γ 
subunit) 
(Benarroch, 2014) 
 
PKA is involved in presynaptic LTP and cAMP-PKA pathway activation 
enhances neurotransmitter release in different brain areas, including hippocampus, 
acting at both excitatory and inhibitory synapses  (Chavez-Noriega and Stevens, 
1994; Trudeau et al, 1996; Wang, 2008). Putative targets of this cAMP-PKA-
mediated effects are the proteins of neurotransmitter release machinery and their 
regulators (Wang, 2008).  
P/Q- and N-type voltage-gated Ca
++
 channels activation triggers 
neurotransmitter release (Currie and Fox, 2002).  
Inward rectifying K
+
 currents are typically postsynaptic and stabilize resting 
potential, while A-type K
+
 currents reestablish resting potential after action 
potential (Currie and Fox, 2002; Takigawa and Alzheimer, 1999; Ruschenschmidt 
et al, 2006). 
Hence, it’s clear how CB1 receptors activation is related to an inhibition of 
neurotransmitter release. 
  
Notably, it’s known that CB1 receptor activation induces extracellular 
signal-regulated kinase (ERK) phosphorylation in growth cones and adult neurons 
(Berghuis et al, 2007; Derkinderen et al, 2003; Dalton and Howlett, 2012). In the 
hippocampus, CB1 receptor-induced ERK activation can be mediated by several 
different pathways, cAMP-pathway included (Derkinderen et al, 2003). Moreover, 
this phenomenon is followed by phosphorilated-ERK (P-ERK) accumulation in the 
nucleus of hippocampal CA1 and CA2 pyramidal cells  and by the expression of 
immediate-early genes product: the protein c-Fos and Zif268 and BDNF mRNAs 
(Derkinderen et al, 2003).  
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CB1 receptors can be homomers or form heterodimers with other receptors, 
possibly activating different downstream pathways as a consequence of this 
interaction.  
eCB-mediated synaptic plasticity 
eCB are responsible for two different types of inhibitory action: phasic and 
tonic. 
The phasic action is an activity-dependent decrease of synaptic strength, 
while the tonic action consists in a basal and constant inhibitory tone. 
The phasic action is the typical eCB retrograde signaling, in which eCBs are 
released on consequence of postsynaptic depolarization and act on presynaptic CB 1 
receptors, mediating short- and long-term depression phenomena both homo- and 
heterosynaptically (Katona and Freund, 2012).  
More specifically, they mediate: 
 depolarization-induced suppression of inhibition (DSI): short-term 
depression of GABA release induced by postsynaptic depolarization 
(Ohno-Shosaku et al, 2001; Wilson and Nicoll, 2001);  
 depolarization-induced suppression of excitation (DSE): short -term 
depression of glutamate release induced by postsynaptic depolarization 
(Kreitzer and Regehr, 2001); 
 long-term depression (LTP) at both glutamatergic and GABAergic 
synapses. 
Short-term plasticity forms are mediated by P/Q- and N-type Ca
++
 channels 
inhibition; long-term plasticity is mediated by cAMP-PKA pathway depression.  
(Benarroch, 2014) 
 
Tonic eCB signaling involve again CB1 receptors and control basal 
neurotransmitter release probability, thanks to a constitutive release of eCBs from 
postsynaptic compartment (Benarroch, 2014; Katona and Freund, 2012). For 
example, in the hippocampus, a reduction in eCB inhibitory tone induces an 
increase in baseline synaptic transmission (Kim and Alger, 2010). 
 
2-AG usually works in phasic signaling, while both AEA and 2-AG work in 
tonic signaling at GABAergic synapses in the hippocampus (Katona and Freund, 
2012). Interestingly, an increase in 2-AG levels determines downregulation of CB1 
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receptors, while this doesn’t happen upon AEA level increase, which in contrast 
grant a sustained agonistic activity (Benarroch, 2014).  
 
eCBs also act on postsynaptic receptors: CB1 and TRPV1. Postsynaptic CB1 
receptors mediate postsynaptic K
+
 channels activation, inducing hyperpolarization 
and inhibiting neuronal excitability. TRPV1 is activated by AEA and  mediates 
postsynaptic LTD at excitatory synapses, while the effects at inhibitory synapses 
remain unknown (Benarroch, 2014). 
CB1 receptor-mediated effects in the hippocampus 
As in most brain areas, in rodent hippocampus CB1 receptors are mainly 
present presynaptically on a subpopulation of GABAergic terminals (i.e. 
cholecystokinin-positive cells), rather than on glutamatergic synapses (Tsou et al, 
1999; Katona et al, 1999; Hajos et al, 2000; Hajos and Freund, 2002; Irving et al, 
2000). Interestingly, the same results were found in human hippocampus (Katona et 
al, 2000).  
 
Many major researches concerning CB1 receptor-mediated eCB signaling 
have been performed in the hippocampus (Hajos and Freund, 2002). DSI, DSE and 
LTD mediated by CB1 receptor has been reported in hippocampus using a specific 
electrophysiological protocol (Ohno-Shosaku et al, 2001; Wilson and Nicoll, 2001).  
Other works along the years have revealed that the administration of the 
CB1 receptor agonist WIN55-212,2 was able to suppress i) [H
3
]GABA release 
evoked by electrical field stimulation (Katona  t al, 1999); ii) evoked inhibitory 
postsynaptic current (eIPSC) amplitude; iii) spontaneous inhibitory postsynaptic 
current (sIPSC) frequency and amplitude in rodent hippocampal slices (Hoffman 
and Lupica, 2000). In hippocampal cultures, the same agonist was able to inhibit 
miniature inhibitory postsynaptic currents (mIPSCs) frequency with no alteration in 
their amplitude (Irving et al, 2000). The involvement of CB1 receptor in these 
effects was proved by the ability of the CB1 receptor antagonist SR141716A to 
totally abolish them (Katona et al, 1999; Hoffman and Lupica, 2000; Irving et al, 
2000). 
Some groups reported some of these WIN55-212,2-mediated effects at 
excitatory synapses too: for example, WIN55-212,2 is shown to suppress evoked 
excitatory postsynaptic currents (eEPSCs) in both cultures (Ohno-Shosaku et al, 
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2002; Sullivan, 1999) and slices (Takahashi and Castillo, 2006) and Dr J. M. 
Sullivan found, in autaptic hippocampal neurons in culture,  that WIN55-212,2 
decreases glutamate release probability and depresses mEPSC frequency (Sullivan, 
1999), though the effect was little and very less prominent than the ones found by 
Dr I. J. Irving and colleagues at inhibitory terminals. However, the studies on CB1 
receptor-mediated effects on excitatory synapses are very controversial: ‘ in 
hippocampus, varying results have been obtained on the extent and site of 
cannabinoid actions on excitatory transmission, ranging from no effect to complete 
obliteration of synaptic responses’  (Bajo et al, 2009). 
Notably, CB1 receptor-mediated effects seem to differ depending on 
neuronal subtype and pathway: e.g. presynapt ic inhibition of both GABA and 
glutamate release mediated by CB1 receptors happens in fibers connected to CA1 
pyramidal neurons, while GABA but not glutamate release is inhibited when the 
postsynaptic neuron is an interneuron (Hoffman et al, 2003). 
eCB signaling and glial cells 
Glial cells are central players in neuromodulation. They are involved in eCB 
signaling and they contain the synthetic machinery for eCB production (Castillo et 
al, 2012). Astrocytes and microglia are demonstrated to produce both 2-AG and 
AEA with microglia releasing high amounts during inflammation (Stella, 2009). 
ATP administration stimulates 2-AG production in both astrocytes (Walter 
et al, 2004) and, through P2X7 activation, in microglial cells (Witting et al, 2004). 
On the other hand, glial cells present functional CB1 and CB2 receptors, which 
regulate inflammation and play neuroprotective roles (Benarroch, 2014). 
A proof-of-principle of the involvement of glial cells in eCB signaling to 
synapses has been provided by the fact that astrocytes , in response to neuronal 
eCBs and through activation of astrocytic CB1 receptors, release glutamate, which 
in turn acts on synapses (Castillo et al, 2012). Astroglial CB1 receptors control 
synaptic transmission and plasticity through different mechanisms ( Oliveira da 
Cruz et al, 2015; Navarrete et al, 2014).  
Also, microglial cells express functional CB1 and CB2 receptors (Stella, 
2009). Microglial CB2 receptor seem to mediate the acquisition of an alternatively 
activated, anti-inflammatory phenotype by microglial cells (Mecha et al, 2015). It’s 
known that microglial cells can modulate synaptic activity through the release of 
neuromodulating factors (e.g. BDNF, TNFα) (Kettenmann et al, 2013). However it 
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has not been clarified whether eCBs produced by microglia can affect synaptic 
activity (Castillo et al, 2012). (for a more detailed description of microglial 
functions see “Microglia” section) 
eCBs in pathology 
In many pathological conditions, high glutamatergic firing induces eCB 
release, which may exert neuroprotective functions. This happens for example in 
neurodegenerative diseases and in traumatic or ischemic brain injuries, thanks to 
the inhibitory effects on glutamate release and the anti-inflammatory functions of 
eCBs. On the other hand, eCB system may play roles in the pathophysiology of 
several diseases, such as seizures, spasticity and movement disorders, pain and 
psychiatric disorders. (Benarroch, 2014)  
 
For example, in some acute models of epilepsy, eCBs play neuroprotective 
and antiepileptic roles, while in other cases they increase seizure susceptibility. 
(Benarroch, 2014) 
Alterations in eCB system have been found also in experimental models 
characterized by movement disorders. In Parkinson’s disease (PD), for example, 
eCB signaling seems to be detrimental for motor symptoms, while its stimulation 
reduces levodopa-induced dyskinesia. Altered eCB system may participate also in 
Hungtington’s disease (HD) pathogenesis, but in this case eCB signaling defect 
aggravates molecular, neuropathological and motor abnormalities. The capability of 
eCBs to reduce motor activity suggests that cannabinoids may be employed in the 
cure of hyperkinetic disorders, such as levodopa-induced dyskinesia or HD. Further 
studies will be necessary for better evaluating the possible use of cannabinoids in 
the therapy for these diseases. (Benarroch, 2014) 
Recent findings point at the endocannabinoid system as a novel potential 
therapeutic target for Alzheimer’s disease (AD). Indeed, eCBs seem to be involved 
in AD pathogenesis. 2-AG signaling is upregulated, while AEA signaling is 
downregulated in the vicinity of Aβ plaques, and overall eCB signaling is likely 
decreased in AD. Although the mechanisms undergoing eCB roles in AD 
pathogenesis are poorly understood, cannabinoid treatment in AD seems to be 
beneficial. eCBs could in fact play anti-inflammatory and neuroprotective roles 
(e.g. reducing excitotoxicity), reduce Aβ plaques and intracellular neurofibrillary 
tangles formation and ameliorate learning and memory deficits (Bedse et al, 2015). 
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Again, there is growing evidence showing the involvement of eCB signaling 
in multiple sclerosis (MS), in both the neurodegenerative and the inflammatory part 
of the disease. eCB release is stimulated in active MS lesions. CB1 receptors seem 
to be manly involved in neuroprotection , by inhibiting ‘the synaptic mechanisms at 
the basis of the neurodegenerative damage’ (i.e. glutamate excitotoxicity; Rossi et 
al, 2011), while CB2 has essentially anti-inflammatory functions (Rossi et al, 
2010). Studies performed on the experimental model of MS (experimental 
autoimmune encephalomyelitis (EAE)) indicated that eCBs are able to restrain 
TNFα-induced excitotoxicity, and proposed it as a plausible mechanism for eCB-
mediate modulation of neurodegenerative damage in MS (Rossi et al, 2011). 
Furthermore, eCBs have been reported to reduce spasticity in MS, by inhibiting 
excitatory wiring and inflammation in the spinal cord, and to effectively  reduce 
central pain and painful spasms typical of this disease (Benarroch, 2014). 
Accordingly, upon spinal cord and nerve injury as well as in neuropathic 
pain models, eCB signaling is upregulated and this seems to have an 
antinociceptive effects. (Benarroch, 2014) 
Relative to psychiatric disorders, dysfunctions of the eCB system may 
participate to the pathogenesis of anxiety-related disorders and depression, while 
pharmacological enhancement of eCB signaling represent a promising therapy for 
the treatment of such disorders. Moreover, eCB neuromodulatory effects may play 
crucial roles in the psychotic-related behaviors observed in animal models of 
schizophrenia (e.g. social and cognitive deficits, altered emotionality). 
Cannabidiol, a non-psychotropic phytocannabinoid, is currently one of the best 
candidates for the therapy of many diseases, included neuropsychiatric disorders. 
(Ghosh and Basu, 2015)  
 
These were just some examples of eCB roles in pathology, given their 
involvement in many brain functions, from memory and cognition to emotion, from 
pain perception to motor control, from feeding behaviors to addiction.  
The effects of exogenous cannabinoid assumption (i.e. cannabis) have not 
been discussed here, as they represent a specific and separate subject.  
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3. Endocannabinoid transport 
eCBs and membranes 
Thanks to their lipidic nature, eCBs present high affinity for membranes. 
They are produced at the inner leaflet of cell membrane (Nicolussi and Gertsch, 
2015). 2-AG is mainly associated with lipid rafts, highly specified domains rich in 
cholesterols where several proteins and receptors are located, while AEA can be 
associated with lipid rafts or not. This has been demonstrated, for example, in BV2 
microglial cell line (Rimmerman et al, 2012; Fowler, 2013). Among membrane 
constituents, cholesterol seems to be very important for AEA uptake and 
translocation through bilayer membrane (Fowler, 2013).  
eCB transport across the membranes and inside the cells 
eCBs are released in the extracellular space and move in this hydrophilic 
environment to reach their target. A challenging and unsolved question is how 
highly hydrophobic fatty acid derivatives, such as eCBs, can cross cell membrane 
and move in the extracellular space (Stanton et al, 2005). Indeed, given AEA or 2-
AG chemical properties, they ‘would be unlikely to enter a hydrophilic solution in 
appreciable quantities unless the concentration gradient was huge’  (Stanton et al, 
2005).  
eCB uptake studies suggest that eCBs trespass cell membrane through 
facilitated (independent on either ATP or ion gradients)  diffusion, in both 
directions. And studies on pharmacological block of AEA uptake , together with 
experiments on FAAH knock-out mice, suggest the existence of an ‘AEA 
membrane transporter’ (AMT) protein, able to specifically remove AEA from the 
extracellular space and relocate it within the cell (Nicolussi and Gertsch, 2015). 
However, the discovery that the inhibitors of AEA uptake was actually not 
selective, acting also on other intracellular AEA carrier and degrading enzymes, 
together with additional issues (e.g. researcher biases in these studies), motivated 
scientists to question the existence of an AMT (Nicolussi and Gertsch, 2015). An 
AMT protein has effectively not been cloned to date. 
Dr C. J. Fowler claimed that data collected so far are consistent also with a 
simpler model, which doesn’t reckon on the binding to a membrane carrier , and 
must be taken into account (Fowler, 2013). On the other hand, Nicolussi and 
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colleagues reported new findings consistent with the existence of an AMT, 
declaring that the molecular identification of the putative AMT would be probably 
just a matter of time (Nicolussi and Gertsch, 2015). 
To date, different models concerning the mechanism of transport of eCBs 
across the cell membrane coexist. The subject is clearly matter of big debate 
(Nicolussi and Gertsch, 2015; Fowler, 2013).  
 
Once inside the cell, AEA is sequestered by intracellular binding proteins 
and receptors or by catabolic enzymes (Fowler, 2013; Maccarrone et al, 2010). 
Many intracellular ‘carrier’ protein that mediate the transfer of AEA from cell 
membrane to intracellular target, have been identified : fatty-acid-binding proteins 
(FABP)-5 and -7, heat-shock protein 70 and albumin (Fowler, 2013; Maccarrone et 
al, 2010). FAAH-like AEA transporter (FLAT) has been proposed as AEA carrier  
as well (Fu et al, 2012), but its role as AEA transporter has been recently 
questioned. Indeed, new studies clarified that this protein actually never contacts 
plasma membrane, while it localizes primarily on intracellular membranes. 
Moreover, it seems that FLAT’s role likely involves its enzymatic function rather 
than its carrier role (Leung et al, 2013).  
A crucial player in AEA concentration gradient maintenance is the AEA 
degrading enzyme FAAH. AEA uptake and FAAH activity are indeed ‘intrinsically 
coupled processes’: FAAH degradation rate greatly affects AEA uptake constants 
in most cell types (Nicolussi and Gertsch, 2015).  
Additionally, it has been recently demonstrated that AEA concentration 
gradient can be maintained also by lipid droplets (adiposomes), which sequester 
and metabolize AEA (Oddi et al, 2008; Kaczocha et al, 2010; Fowler, 2013; 
Maccarrone et al, 2010). 
 
Starting from these knowledge, Nicolussi and Gertsch, 2015 listed the 
following models: 
1. Passive diffusion driven by FAAH activity: FAAH degrades AEA thus 
creating a concentration gradient which favors AEA passive diffusion 
throughout plasma membrane . In this model, FAAH activity ‘ is the major 
driving force for AEA diffusion’. 
2. Passive diffusion driven by carrier-mediated intracellular transport and 
sequestration: an updated ‘model 1’ in which the driving force generated by 
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intracellular carrier activity is taken into account (Fowler, 2013) (Figure 
IVA).    
3. ‘Facilitated diffusion and carrier-mediated intracellular transport of AEA’: 
‘AEA associates with the plasma membrane and accumulates in certain 
domains where it binds to a specific high-affinity membrane transporter 
protein (AMT) that facilitates translocation of its substrate rapidly toward 
the inner leaflet of the lipid bilayer’  (Nicolussi and Gertsch, 2015); once in 
the cytosol, AEA binds to intracellular carriers which drive them t o targets 
or degrading enzymes (Figure IVB) 
4. ‘Endocytosis-mediated AEA uptake and intracellular sequestration ’: AEA 
binds to a carrier protein located within plasma membrane lipids rafts and it 
is internalized through caveolae-dependent endocytosis (Figure IVC) 
(Nicolussi and Gertsch, 2015) 
 
Different routes can likely be used by cells for eCB uptake, for example 
‘depending upon whether they employ eCBs as signaling molecules or as a source 
of arachidonic acid’ (Fowler, 2013). 
 
As you can see, most of the studies to date concern AEA rather than 2-AG 
cellular transport. One reason is the fact that 2-AG is more rapidly degraded than 
AEA and thus more difficult to be quantified (Nicolussi and Gertsch, 2015). 
However, according to literature, 2-AG cellular uptake seems to be very similar to 
the one of AEA (Nicolussi and Gertsch, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV  Models of AEA transport through the plasma membrane: A. Passive diffusion driven by carrier-
mediated intracellular transport and sequestration model; B. Facilitated diffusion and carrier-mediated 
intracellular transport of AEA; C. Endocytosis-mediated AEA uptake and intracellular sequestration.               
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eCB release and extracellular trafficking 
Little is known about eCB release. We don’t know whether it  has to be 
considered as an uptake process in reverse or whether involves a separate route 
(Fowler, 2013), even if there are evidence strongly supporting the first hypothesis 
(Nicolussi and Gertsch, 2015).   
Extracellular eCB carriers have been proposed to be responsible of 
removing eCB molecules from donor cell membrane and facilitating their 
interaction with specific receptors on target cell membrane. These are probably 
circulating binding proteins, with albumin and lipocalins as putative molecules. 
Indeed, albumin is known to work as a carrier for fatty acids moving from one cell 
to the other in the blood and it has been demonstrated that this protein  is very 
effective in delivering eCB-based drugs in vitro (Stanton et al, 2005). Lipocalins 
are a family of proteins capable of binding small hydrophobic molecules, 
interacting with specific plasma membrane receptors and creating complexes with 
soluble macromolecules (Flower, 1996). However, to my knowledge, a fatty acid 
binding protein specific for eCB has not been identified yet.  
Another hypothesis that has been proposed through the years is that eCBs 
might bind transsynaptic proteins, such as Eph-Ephrin or neurexin-neuroligin pairs 
in their hydrophobic domains to reach the other side of the synapse, or that this 
may happen by a process similar to trans-endocytosis (Stanton et al, 2005). 
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4. Extracellular vesicles (EVs) 
In my laboratory, we are studying extracellular vesicles (EVs): a newly 
emerged and very important mechanism of cell-to-cell communication (Cocucci 
and Meldolesi, 2015; Raposo and Stoorvogel, 2013). Often visualized by electron 
microscopy, EVs had been long considered as mere cellular debris. However, we 
now know they play crucial roles in intercellular cross-talk in prokaryotes till 
plants and higher eukaryotes (Yanez-Mo et al, 2015; Gyorgy et al, 2011; Cocucci 
and Meldolesi, 2015). 
EVs are membrane structures capable of collecting all sorts of bioactive 
molecules (protein, nucleic acids, lipids) from a donor cell and delivering them to 
specific target cells (Figure V). Recipient cells may be in the vicinity or even far 
away from their origin (Yanez-Mo et al, 2015); indeed, membrane shell of EVs 
preserve their contents from degradation (Cocucci and Meldolesi, 2015). EVs are 
released by virtually every cell type and their components , and the signals 
transmitted, reflect the nature and activation state of the donor cell (Cocucci et al, 
2009; Fruhbeis et al, 2013). 
 
 
 
Figure V   EVs are membrane structures capable of collecting all sorts of bioactive molecules (protein, nucleic 
acids, lipids) from a donor cell and delivering them to specific target cells 
- 27 - 
 
EVs have been found to be secreted also in vivo (Raposo and Stoorvogel, 
2013; Verderio et al, 2012); and they have been detected in several body fluids, 
including cerebrospinal fluid (Verderio et al, 2012), blood, urine, faeces, saliva, 
seminal fluid, breast milk, amniotic fluid, synovial fluid, broncho alveolar fluid, 
nasal secretion, ascites fluid and bile (Raposo and Stoorvogel, 2013; Yanez-Mo et 
al, 2015). 
Hence, no wonder that they are reported to influence several physiological 
and pathological processes (Yanez-Mo et al, 2015), such as neuromodulation, 
inflammation, coagulation, angiogenesis, tumor progression and others, yet 
depending on the nature and state of parental cells (Antonucci et al, 2012; Nakano 
et al, 2015; Rajendran et al, 2014; Smith et al, 2015). For that reason, they have 
been proposed as prognostic (Ratajczak et al, 2006) and diagnostic tools (e.g. 
markers of inflammation, Colombo et al, 2012; Verderio et al, 2012), therapeutic 
agents or  target agents (Thery et al, 2009; Verderio et al, 2012), and as drug 
delivery systems (Ratajczak et al, 2006), thanks to their dimensions and ability to 
access several biological fluids (Gyorgy et al, 2011). 
 
 
 
 
 
Figure VI  MV and exosome origin. MVs bud directly from the plasma membrane through a process called 
shedding. Conversely, exosomes originate inside multivesicular bodies. 
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Two kinds of EVs have been described so far: microvesicles (MVs) and 
exosomes. MVs shed directly from the plasma membrane. They are more 
heterogeneous and larger then exosomes, displaying a diameter of 100 nm to 1 μm 
(Cocucci and Meldolesi, 2011; Mause and Weber, 2010; Raposo and Stoorvogel, 
2013). Exosomes, on the other hand, originate inside multivesicular bodies and are 
released after fusion of multivesicular bodies themselves with the plasma 
membrane. They are more homogeneous and smaller compared to MVs, ranging 
from 40 to 100 nm in diameter (Mause and Weber, 2010; Raposo and Stoorvogel, 
2013; Simons and Raposo, 2009). (Figure VI) Exosomes are constitutively 
released, while MV secretion undergoes a drastic increase after stimulation. The 
two populations have distinct characteristics and may exert distinct functions, in 
spite of several overlapping roles (Gabrielli and Verderio, in print; Cocucci and 
Meldolesi, 2015). 
Biogenesis and sorting 
Recent studies enlightened the role of proteins and membrane lipids in the 
budding and pinching off of EVs. For example, tetraspanins, endosomal sorting 
complex responsible for transport (ESCRT) complexes  (with a crucial role for the 
ESCRT-I subunit Tsg101 and for ESCRT-III) and their accessory proteins (e.g. 
Alix), the membrane lipid ceramide and its synthetic enzyme sphingomyelinase, 
other integral proteins and glycoproteins have been reported to be involved in EV 
biogenesis (Raposo and Stoorvogel, 2013). EV pinching off is likely triggered by 
raising of  intracellular Ca
++
 concentrations and requires cytoskeleton remodeling, 
involving microtubules, actin and the molecular motors myosins and kinesins, 
together with small GTPase protein (i.e. Rab11, Rab27 and Rab35) and a SNARE 
(Soluble NSF Attachment protein REceptors) fusion machinery (Raposo and 
Stoorvogel, 2013). On the other hand, we know from literature that stimulated 
release of MVs happens, at least in some cell  types (i.e. microglia, macrophages 
and dendritic cells), in response to adenosine-5'-triphosphate (ATP)-dependent 
activation of the P2X7 purine receptor (Bianco et al, 2005; Cocucci and Meldolesi, 
2015). However, the mechanisms underlying these processes seem to be complex 
and remain largely unclear (Raposo and Stoorvogel, 2013). 
The same applies to the sorting process, by which specific molecules 
segregate inside EVs. During vesicle assembly, proteins, lipids, various RNAs 
(mRNAs, siRNAs, long non coding RNAs, miRNAs), and all the molecules which 
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will be included in EVs, gather in the vicinity of the budding area, into small 
microdomains, through a not yet completely defined process. (Raposo and 
Stoorvogel, 2013; Cocucci and Meldolesi, 2015)  
What we know is that cholesterol, sphingomyelin and its metabolite  
ceramide are usually sorted in both types of EVs. This is not the case for other 
lipids and membrane proteins, which are specific of MVs or exosomes or present 
only on EVs derived from certain cell types. Cargo protein segregation happens 
more for MVs rather than for exosomes. And, in the case of MVs, this process 
requires ESCRT complexes and the binding of cytoplasmic proteins to the cell 
membrane thanks to plasma membrane anchors (e.g. palmitoyl, myritroyl  residues) 
or after their polymerization. Other proteins bind these anchored complexes to be 
sorted as well. (Cocucci and Meldolesi, 2015)      
Membrane proteins enriched in microdomains, such as tetraspanins (CD63, 
CD81, CD82, CD53 and CD37), are usually highly present in EVs, as well as 
protein associated with lipid rafts, such as flotillin and 
glycosylphosphatidylinositol-anchored proteins. On the other hand, a pure EV 
sample will be free of serum proteins and intracellular compartment contaminants, 
such as mithocondria, endoplasmic reticulum and nucleus components. (Raposo and 
Stoorvogel, 2013) 
Interaction with donor cell 
EVs can deliver their signals in different ways (Figure VII). Some of them 
break down and release soluble molecules in the extracellular space: in this way are 
release, for example, interleukin-1β (IL-1β) and other tissue and growth factors, 
including transforming growth factor beta (TGFβ) . Other EVs remain intact and can 
move far away from the releasing point: these are the so called navigating EVs, 
detected in body fluids. 
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Figure VII   EV interact with donor cells in different ways: they can undergo a ligand-receptor interaction 
with specific membrane molecules present on neuronal surface; they can fuse with the plasma membrane and 
transfer their cargoes directly inside the cytoplasm of donor cell; or they can be internalized through endocytosis 
and subsequently fuse with endosomal membrane to release their content in the cytosol. Alternatively, they can 
break down and release soluble factor in the extracellular space. 
 
 
EVs can also make contact with donor cells. (Figure VII) The binding to the 
recipient cell is target-specific and is likely mediated by adhesion molecules (e.g. 
integrins, ICAM-1, MHC class II) present on EV surface. Tetraspanin complexes 
and galactins are also involved in target cell specificity (Raposo and Stoorvogel, 
2013). The binding of EVs with surface proteins or receptors is usually preceded by 
the rolling of the vesicle over cell surface (Cocucci and Meldolesi, 2015). After the 
binding to the target cell, EVs can stay or dissociate. They can fuse with the plasma 
membrane and transfer their cargoes inside the cytoplasm of donor cells. This is 
called a direct transfer and happens usually in the case of genetic material and 
cytoplasmic proteins. In case of fusion, receptors and other molecules present on 
EV surface are transferred to donor cell membrane  too. Finally, EVs can undergo 
endocytosis, through different mechanisms (e.g. Clatrin-dependent, phagocytosis, 
macropinocytosis). Internalized EVs can then be released in the cytosol or face 
lysosomal degradation.  
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5. Microglial MVs 
Within the CNS, neurons (Doeuvre et al, 2009), oligodendrocyte, astrocytes 
and microglial cells all have been reported to release EVs. According with 
literature, EVs participate in neurite outgrowth and neuronal survival and in myelin 
formation (Raposo and Stoorvogel, 2013). Several molecules involved in the 
pathogenesis of brain diseases, such as prion protein, β-amiloid (Aβ) protein, α-
sinuclein, are secreted in association with EVs (Raposo and Stoorvogel, 2013). 
 
In my laboratory we are focusing our studies on EVs released by glial cells. 
A few years ago the lab reported how glial cells release MVs upon ATP 
activation (Bianco et al, 2009; Bianco et al, 2005) (Figure VIII, left). To induce 
MVs release ATP must activate P2X7 receptors, which respond to high ATP 
concentration (Farber and Kettenmann, 2006; Lalo et al, 2011) reached usually 
under inflammatory conditions (Davalos et al, 2005; Fiebich et al, 2014). 
 
 
 
 
Figure VIII  On the left, fluorescence images of N9 
microglial cell lines loaded with FM1-43 dye during BzATP 
exposure (modified from Bianco et al, 2009); BzATP: P2X7 
selective agonist- benzoyl ATP; on the right, electron 
microscopy images of MVs (P2, P3) and exosomes (P4) 
released by glial cells upon P2X7 activation; MPs: 
microparticles (modified from Bianco et al, 2009). 
 
 
 
Subsequently, microglial MVs have been deeply characterized through 
several different methods: electron microscopy, fluorescence microscopy, 
fluorescence activated cell sorting (FACS), western blotting, spectrometric analysis 
(Bianco et al, 2009; Bianco et al, 2005) (e.g. see Figure VIII, right). 
MV release was preceded by repeated protrusion and retraction of 
membrane blebs and by phospholipid phosphatidylserine (PS) exposure on the outer 
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leaflet of plasma membrane. Although these are both apoptotic signals,  MV release 
was demonstrated to be independent from programmed death phenomena (Bianco et 
al, 2009; Bianco et al, 2005). PS residues function is likely to facilitate MVs 
contact with neuronal surface, through a ligand-receptor interaction (Antonucci et 
al, 2012) (Figure X).   
 
 
 
 
 
 
Figure IX  Model for MV release mediated by the pathway downstream P2X7 activation in glial cells. See 
the text for description. BzATP: P2X7 selective agonist- benzoyl ATP; A-SMase, A-SM: acid sphingomyelinase 
(Bianco et al, 2009) 
 
 
Subsequent experiments performed in the lab enlightened the molecular 
mechanisms underlying MV release from glial cells (Figure IX). ATP-P2X7 
pathway activation involves Src kinase and induces P38-MAPK phosphorylation. 
This determines the translocation of the enzyme acid sphingomyelinase (A -SMase) 
from the lysosomal compartment to the outer membrane leaflet, wherein it 
facilitates MV budding, thanks to the conical geometry of its product ceramide. 
The budding of MVs likely happens in the lipid rafts. (Bianco et al, 2009) 
 
Microglial MVs contain the key cytokine of acute inflammation IL1 β, which 
is produced from its precursor, pro-IL1β, inside the vesicles and subsequently 
released in the extracellular space in a regulated manner (Bianco et al, 2005). 
Furthermore, ATP-induced MV release was increased in reactive microglia, 
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exposed to endotoxin LPS or TH1 cytokines, responsible of driving microglia 
towards an inflammatory phenotype (Verderio et al, 2012). 
 
In vivo existence of microglial MVs was also reported by my laboratory. 
Indeed, “MVs positive for typical microglial markers were detected by electron 
microscopy and confocal microscopy in the cerebrospinal fluid (CSF) collected 
from rodents and humans” (Verderio et al, 2012; Gabrielli and Verderio, in press). 
Interestingly, higher levels of MVs are concomitant with activated microglia status: 
MV concentration was found increased in the CSF of mice with experimental 
autoimmune encephalomyelitis (EAE; mouse model of multiple sclerosis), during 
symptomatic phases, and in the CSF of multiple sclerosis patients in the acute 
phase of the disease (Verderio et al, 2012). More importantly, data indicated that 
MVs released from reactive microglia spread inflammatory signals (such as pro-
inflammatory cytokine IL-1β) to other glial cells, thus contributing to 
neuroinflammation (Verderio et al, 2012; Gabrielli and Verderio, in press) . 
 
Again, electrophysiological recordings on cultured rat hippocampal neurons 
showed that MVs, released from microglia upon ATP activation, are able to induce 
an increase in glutamate release probability. And we demonstrated that MV-
induced potentiation of excitatory transmission was mediated by the sphingolipid 
Sphingosine (Sph) whose production in neurons is increased by microglial MVs 
themselves (Antonucci et al, 2012) (Figure X). 
 
Furthermore, a proof-of-principle that microglia MVs can acutely alter 
neurotransmission also in vivo came from electrophysiological recordings of the rat 
visual cortex after injection of microglial MVs (Antonucci et al, 2012). Microglial 
MVs induced a significant increase in the amplitude of visual evoked potentials 
(VEPs) evoked by high contrast stimuli, which reflects the sum of excitatory 
currents induced by sensory stimulation (Porciatti et al, 1999; Restani et al, 2009). 
In addition, single unit recordings revealed an increase in neuron receptive fields 
after MV injection, which is typically determined by an alteration of 
excitatory/inhibitory balance (Benali et al, 2008; Liu et al, 2010). (Gabrielli and 
Verderio, in press). 
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Figure X   MV effects on excitatory synapses. Phosphatidilserine (PS) residues exposed on MV surface bind to 
their specific neuronal receptor, thus facilitating MV interaction with neuronal surface. Subsequently, an 
unknown lipid present on MV membrane stimulates sphingolipid metabolism in neurons. The sphingolipid 
sphingosine (Sph) and sphingosine-1-phosphate (S1P) are the effectors, responsible for increasing glutamate 
release probability and inducing synapsin I (Syn I) dispersion respectively (Antonucci et al, 2012; Riganti et al, 
submitted). SM: sphingomyelin; Cer: ceramide. 
 
 
Additionally, we showed that the sphingolipid cascade induced by MVs 
goes up to sphingosine-1-phosphate (S1P), which participates to presynaptic 
stimulation by inducing dispersion into the cytoplasm of synapsin I (SynI), a 
presynaptic phosphoprotein that regulates the availability of synaptic vesicles for 
exocytosis (Riganti et al, submitted) (Figure X). Both Sph and S1P increase the 
number of synaptic vesicles of the readily releasable pool, ready to be exocytosed 
upon action potential. 
 
Microglia-derived MVs communicate with neurons also through another 
mechanism: the direct transfer of their cargo. Recent findings from my laboratory 
indicate that miR-146a is transferred from microglial MVs to neurons, decreasing 
the expression of synaptotagmin I, a validated miR-146a target (Prada et al, 
unpublished).  
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Further evidence indicates that microglial MVs participate to degeneration 
in Alzheimer’s disease thanks to i) formation of soluble (more toxic) Aβ species by 
MV lipids from extracellular insoluble aggregates; ii) the shuttling of neurotoxic 
Aβ species by MVs produced by Aβ-containing microglia (Joshi et al, 2014). 
 
Again, microglial MVs have been found to promote oligodendrocytes 
precursors (OPC) differentiation in culture and myelin deposition in OPC -DRG 
neurons co-coltures  (M. Lombardi and C. Verderio, unpublished data). 
 
Finally, we took advantage of optical tweezers technique combined to live 
imaging to drive single microglia-derived EVs on the surface of astrocytes, 
microglia or neurons in culture and study their behavior (Prada et al, in print; Prada 
et al, unpublished data). Through these experiments we confirmed that PS residues, 
externalized on the outer membrane of MVs, play an important role for MV 
recognition by target cells. In fact, the cloaking of these residues effectively 
reduced MV interaction with both glial and neuronal surface (Prada et al, in print; 
Prada et al, unpublished). Ongoing optical manipulation experiments on MV 
interaction with neuronal surface are revealing an unexpected and complex 
trafficking of MVs outside the surface of neurons, which may underlie the 
activation of contact-mediated signaling pathways and regulate the transfer of MV 
cargo in specific neuronal compartments (Prada et al, unpublished).  
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6. Microglia 
Microglial cells are the innate immunity cells resident in the brain. They are 
myeloid cells, similar to macrophages in features and functions. (Kettenmann et al, 
2013) 
In the normal brain, microglia are in a resting/surveillant status, 
characterized by a ramified morphology. In response to specific  stimuli, they get 
activated: they assume an amoeboid morphology and specialize for operate in a 
pathological environment, becoming active phagocytes. (Kettenmann et al, 2013) 
(Figure XI) 
 
 
 
 
 
Figure XI  Microglial cell activation. Resting microglial cells are stimulated by different stimuli to reach first a 
primed state, characterized by an increase in the expression of cell-surface markers, and after a triggering 
stimulus  an activates state, characterized by the release of high doses of pro-inflammatory cytokines (modified 
from Dilger and Johnson, 2008). 
 
 
Microglia respond to two classes of signals: ‘on signals’, which push them 
toward activation, and ‘off signals’, which turn them away from activation (Biber 
et al, 2007; Kettenmann et al, 2013). ATP, together with other purines, chemokines 
and glutamate, are typical ‘on signals’. They are usually released from damaged 
tissues, but also from neurons which are hyperactive in a regulated manner ( Biber 
et al, 2007). On the other hand, a typical ‘off signal’ is the binding of neuronal 
surface proteins with their specific microglial receptors, a signal of neuronal 
integrity (Biber et al, 2007). Notably, microglia sense neuronal activity, thanks to 
the plethora of receptors for neurotransmitter, and other neuromodulator, which 
express (Pocock and Kettenmann, 2007).  
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Microglial cells integrate all the signals they receive, showing an 
heterogeneous range of activation states: microglia may show several different 
phenotypes, both pro- and anti-inflammatory, depending on the stimuli they 
receive, on the kind of disease and on its phase (Kettenmann et al, 2013; 
Kettenmann et al, 2011; Hanisch and Kettenmann, 2007). 
 
In pathology, microglial cells exert different functions. Acquiring an 
amoeboid phenotype, they move, following chemotactic gradients, to the site of 
damage. They release chemotoxic agents to fight pathogens, recall other immune 
cells and work as antigen presenting cells to T cells. Finally, they clean up from 
dead cells and debris.  
All brain pathologies are characterized by microglia activation. However, in 
some case, microglia activity is neurotoxic and promotes the progression of the 
pathology, while in others it seems to be beneficial, important for resolution and 
tissue regeneration. This dualism appears to be due to different activation signals. 
(Hanisch and Kettenmann, 2007; Kettenmann et al, 2011; Graeber and Streit, 2010; 
Perry et al, 2010)   
 
Although microglia play central roles in all the inflammatory processes 
which take place in the CNS, there is growing evidence that these cells play also 
several important physiological roles (Kettenmann et al, 2013). 
During development, ‘resting’ microglial cells release growing factors 
which promote synaptogenesis and mediate the controlled elimination of synapses 
(e.g. synaptic pruning), which is essential for the constitution of a functional 
neuronal network (Kettenmann et al, 2013; Paolicelli et al, 2011; Paolicelli and 
Gross, 2011; Zhan et al, 2014).  
In the adult brain, microglia release several molecules which affect neurons, 
such as cytokines, trophic factors, neurotransmitters, even in physiological 
situations. (Kettenmann et al, 2013) Microglia can affect synaptic plasticity. For 
example, on consequence to a prolonged change in synaptic activity, they release 
low doses of tumor necrosis factor alpha (TNFα) which adapt the strength of the 
synapses in the network to the change (i.e. synaptic scaling) (Stellwagen and 
Malenka, 2006). Furthermore, microglia regulate the integration of newly generated 
neurons in the net, contributing to adult neurogenesis, and remove unnecessary and 
apoptotic neurons. (Kettenmann et al, 2013)      
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Finally, it has been recently reported that resting microglia, far from being 
inactive, have very mobile processes able to sense signals from their environment 
(Davalos et al, 2005; Nimmerjahn et al, 2005). In the normal brain, microglial 
processes typically target synapses, making several brief but repetitive contac t 
which are likely activity-dependent (Wake et al, 2009; Tremblay et al, 2010; 
Fontainhas et al, 2011), while Davalos et al, 2005 provided evidence of their ATP-
mediated nature (Kettenmann et al, 2013).  
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AIM OF THE THESIS 
Active endocannabinoids (eCBs) are important lipid mediators in the brain. 
They are secreted by neurons and their main function is to inhibit GABA and 
glutamate release from presynaptic terminals  acting on their specific receptors, 
called CB1 receptors. Glial cells produce eCBs too, with microglia likely 
representing the main source under inflammation. How these highly hydrophobic 
molecules can cross cell membrane and move in the extracellular space to exert 
their function was still largely unknown. 
On the other hand, in my laboratory we work on extracellular vesicles (EVs) 
of microglial origin. EVs may represent an ideal vehicle for the transport of 
hydrophobic mediators in the brain. They are membrane structures which work as 
shuttles for active molecules, from a donor to a target cell. Two kinds of EVs have 
been described so far: exosomes, which originate in the endocytic compartment; 
and microvesicles (MVs), which bud directly from the plasma membrane. Hence, in 
this thesis we aimed at exploring the possibility that eCBs may be released from 
microglial cells in association with EVs, thus influencing neurotransmitter release. 
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RESULTS 
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EV quality control  
Extracellular vesicles (EVs), released in the supernatant of microglial cells 
after 1h stimulation with 1 mM ATP, were collected through differential 
centrifugation, after clearing by cell debris, as described in “Materials and 
Methods”. For some of the experiments, a mixed EV population, containing both 
microvesicles (MVs) and exosomes, and obtained through a 100,000g 
centrifugation, was used; for other sets of experiments, MV- and exosome-enriched 
pellets, obtained by centrifuging at 10,000g and 100,000g respectively, were 
employed. 
 
EV isolation is a crucial step in order to avoid the presence of contaminants 
(i.e. subcellular organelle components, vesicles produced by damaged cells, etc) in 
the samples, which may create artifacts. Moreover, EV yield can vary among 
different cell preparations. Hence, although microglial EVs had been already 
extensively characterized in the laboratory (see “Introduction”), EV quality control 
has been carried out routinely. EV production and sample purity have been checked 
through i) Nanoparticle Tracking Analysis (Figure 1A); ii) quantification of protein 
content through Bicinchonic acid (BCA) assay (Figure 1B); iii) western blot 
analysis for the EV markers Tsg101 (Joshi et al, 2014; Nabhan et al, 2012), flotillin 
and Alix, and for markers of subcellular organelles and lipid droplets (Figure 1C).  
Nanoparticle Tracking Analysis of MV- and exosome-enriched pellets 
reflected data reported in literature (Raposo and Stoorvogel, 2013) (Figure 1A). 
Tsg101 stained both MV and exosome fractions, flotillin was found enriched in 
MVs, while Alix stained preferentially exosomes. The absence of immunoreactivity 
for typical markers for nucleus (SP1), mitochondria (TOM20), Golgi reticulum 
(GS28) and lipid droplets (Adipophilin; Straub et al, 2013) excluded the presence 
of contaminants in the samples.  
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Figure 1  EV quality control  
 
A. Representative plots for particle size distribution of MV- (left) and exosomes- (right) enriched 
fractions pelleted from 1 × 106 primary microglia and resuspended in 400 μl of 0.1-μm-filtered 
sterile KRH. Normalized EV concentration: MVs = 1 ± 0.05, exosomes = 1.2 ±0.2 (N = 3). 
B. Protein quantification of MVs and exosomes produced by 1×106 primary microglia (N = 14). 
 
C. Western blot analysis of MV- and exosome-enriched fractions produced from 1×107 primary 
microglia using the specified antibodies. Notably, there was no immunoreactivity for nuclear, 
mitochondrial and Golgi markers (SP1, TOM-20, GS28 respectively) and for the lipid droplet 
marker Adipophilin. In the first two lanes lysates from 2×105 and 0.4×105 cells was loaded. 
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AEA is enriched in MVs and exosomes 
released from microglial cells 
First aim of the project was to evaluate whether endocannabinoids (eCBs) 
may be released by microglia in association with EVs. To address this question, 
eCB content in mixed EV pellets and in MV- and exosome-enriched fractions were 
measured through mass spectrometry. Detectable amounts of N-
arachidonoylethanolamine (anandamide, AEA) were found in mixed EV pellets 
produced by N9 microglia cell line and primary microglia, as well as in 
corresponding parental cells; while 2-arachidonoylglycerol (2-AG) levels were not 
detectable in all the samples tested (the limit of detection of the instrument is 0.2 
pmol/mg of protein). Notably, a clear enrichment in AEA was found in EVs 
compared to donor N9 (~2900-fold enrichment) or primary microglial cells (~120-
fold enrichment) (Figure 2A). These data indicate that the eCB AEA is released 
from microglial cells carried by EVs.  
Interestingly, AEA content was higher in MVs compared to exosomes  
(Figure 2B). On consequence, we focused our attention on MVs, which were used 
in all subsequent experiments.  
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Figure 2   AEA is enriched in MVs and exosomes released from microglial cells 
 
A. AEA content in EVs versus corresponding donor N9 cells (N = 2), or primary rat microglia (N = 
4). Student’s t-test, P < 0.05, P < 0.001 
 
B. AEA content in MVs and exosomes versus parental primary microglia (N = 3). One-way 
ANOVA, P < 0.0001, followed by Bonferroni  test for comparison among groups, P < 0.0001  
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Hippocampal primary cultures are a suitable 
system to bioassay eCB activity 
A well-known function of AEA is to inhibit GABA release acting on 
presynaptic CB1 receptors on inhibitory terminals and electrophysiological 
recordings are usually used as a readout for AEA activity (Benarroch, 2014; Katona 
and Freund, 2012). Hence, in order to explore the possibility that eCBs present in 
MVs may induce a functional response in neurons, patch clamp analysis of 
spontaneous inhibitory postsynaptic currents (mIPSC) on cultured hippocampal 
neurons were employed to bioassay vesicular AEA activity.  
 
However, since the majority of the studies in this field were performed on 
slices, hippocampal primary cultures were first validated as a suitable system to 
detect AEA activity. According to literature (Tsou et al, 1999; Katona et al, 1999; 
Hajos et al, 2000; Hajos and Freund, 2002; Irving et al, 2000), CB1 receptors are 
expressed in a subpopulation of GABA-ergic interneurons rather than in 
glutamatergic neurons, as indicated by the triple-stained immunofluorescence 
analysis showed in Figure 3A-B. Consistent with CB1 receptor expression pathway 
and with literature, the acute administration of the CB1 receptor agonist 
WIN55,212-2 (1 μM) induced a strong reduction of mIPSC frequency, while wasn’t 
able to induce any major alteration on mEPSCs (miniature excitatory postsynaptic 
currents) (Figure 4A). 
As a further proof of CB1 receptor functionality in culture, calcium imaging 
analysis of calcium responses after acute administration of the CB 1 receptor agonist 
WIN55,212-2 was performed. Indeed, we knew from literature that WIN55,212-2-
induced CB1 receptor activation drives to an increase of intracellular calcium levels  
(Lauckner et al, 2005). The acute application of WIN55,212-2 (1 μM) to 
hippocampal cultures induced calcium transients in a subpopulation of neurons 
(Figure 4B); according to the other evidence. 
Thus, we concluded that hippocampal primary cultures maintain several 
aspects of in vivo physiology, included the expression of functional CB 1 receptors 
on interneuron presynaptic terminals. 
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Figure 3  Hippocampal primary cultures express CB1 receptors on a subpopulation of GABAergic neurons 
rather than on glutamatergic neurons 
 
A. Immunofluorescence images of 17 DIV hippocampal neurons with CB1 receptor in red, the 
glutamatergic marker VGLUT in green and the GABA synthetic enzyme GAD (glutamic acid 
decarboxylase) in blue. CB1 receptors colocalize with a subpopulation of GAD-positive neurons 
rather than with VGLUT-positive neurons; scale bar: 25 m; 
 
B. Areas selected in A at higher magnification; scale bar: 12 m 
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Figure 4   Functional CB1 receptors are expressed in a subpopulation of GABAergic neurons 
 
A. Effects of CB1 receptor agonist WIN55,212-2 (arrow) acute administration on mIPSC (top) and 
mEPSC (bottom): after WIN55,212-2 (1 μM) application a strong reduction of mIPSC frequency 
was found; while no visible alteration of mEPSC was detected  after treatment 
 
B. Representative calcium imaging plot of calcium responses in hippocampal neurons after 
WIN55,212-2 acute application (arrow) 
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Microglia MVs inhibit GABA spontaneous 
release through activation of CB1 receptors 
After validating hippocampal cultures as biosensor for eCB activity, we 
evaluated whether eCBs present in MVs were able to induce a functional response 
in neurons in culture taking advantage of patch-clamp technique. Rat hippocampal 
neurons were exposed for 40-45 min to MVs produced by primary microglial cells 
(1.2 μg/ml, 10,000g pellet) and mIPSC were recorded. The results showed a 
significant reduction of mIPSC frequency in MV-treated neurons compared to 
control cells (Figure 5A-B), while no alteration in mIPSC amplitude was found 
after MV administration (Figure 5A,C), according with a presynaptic nature of MV 
action. Notably, the effects of MV treatment mimicked the ones of CB1 receptor 
agonist WIN55,212-2 (see Figure 4A).  
The role of eCBs present in MV-enriched fraction in this inhibition of 
GABA spontaneous release was indicated by the capability of the selective CB1 
receptor antagonist SR141716A (Rimonabant, 1 μM) to completely abolish MV-
mediated depression of mIPSC frequency (Figure 6A). The administration of 
SR141716A (1 μM) alone was ineffective on mIPSC frequency (Figure 6A), 
according with literature (Irving et al, 2000).  
eCBs present in 10,000g MV-enriched fraction and responsible for this 
action may still have been released in association with other structures which may 
co-purify with MVs, such as lipid droplets or micelles. To rule out the possibility 
that eCBs could be release through a non-vesicular pathway, we pharmacologically 
blocked MV release by administrating to microglia the P2X7 receptor antagonist 
oxidized ATP (oATP, 100 μM; Bianco et al, 2005) and then proceeded with the 
standard protocol for MV isolation. oATP blocks ATP-mediated release of MVs 
(Bianco et al, 2005) allowing constitutive release only. The obtained 10,000g pellet 
was completely ineffective on mIPSC frequency (Figure 6B), thus demonstrating 
that the eCBs accounting for mIPSC frequency decrease are actually carried by 
MVs.  
These findings demonstrate that microglial cells release active eCBs through 
a vesicular pathway and that eCBs stored in MVs play a crucial role in the 
modulation of inhibitory transmission in the brain. 
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Figure 5   Microglia MV treatment depresses mIPSC frequency 
 
A. Representative mIPSC traces of control and MV-treated 16-17 DIV hippocampal neurons 
 
B. Effect of microglial MV treatment (10,000 g pellet from primary microglia, incubation lasted 
40-45 min) on mIPSC frequency in 16-17 DIV hippocampal cultures (N=5, normalized data);  
Mann–Whitney Rank-sum test, P = 0.004; Ctrl n = 35 cells, MVs n = 35 cells 
 
C. Effect of microglial MV treatment on mIPSC amplitude (N=5, normalized data);  Mann–Whitney 
Rank-sum test, P = 0.428, Ctrl n = 35 cells, MVs n = 35 cells  
 
  
- 50 - 
 
 
 
 
 
 
 
 
 
Figure 6   Microglia MV treatment depresses mIPSC frequency through activation of CB1 receptors 
 
A. MV action on mIPSC frequency is blocked in the presence of the CB1 receptor antagonist 
SR141716A , administrated at the effective dose of 1 μM for 15 min before and together with 
MV treatment (N =5); One-way ANOVA, P < 0.001, followed by Bonferroni test for comparison 
among groups, P < 0.05, P < 0.01 
 
B. oATP inhibit MV release through blockade of P2X7 receptor, responsible for MV shedding; 
10,000 g pellet produced from primary microglia pre-treated with oATP (100 μM), lacking of 
MVs, wasn’t able to induce any alteration in mIPSC frequency (normalized data; N = 3); 
Kruskal–Wallis ANOVA, P = 0.006, followed by Dunn’s tes t for comparison among groups, P < 
0.05 
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MV-mediated CB1 receptor activation drives 
to a downstream signaling in neurons 
It’s known from literature that CB1 receptor activation leads to ERK 
phosphorylation (Dalton and Howlett, 2012). Hence, in order to investigate whether 
MV-induced activation of CB1 receptor could drive to an intracellular signaling 
pathway activation, we performed western blot analysis for total and 
phosphorylated-ERK (P-ERK). The results revealed an increase in P-ERK levels 5 
min after MV exposure (Figure 7). This effect was completely blocked by co-
administration of the  CB1 receptor antagonist SR141716A (1 μM) (Figure 7).  
These data corroborate the fact that eCBs present in MVs are active on 
neurons and indicate that MV-mediated activation of CB1 receptor actually 
translates into downstream signaling in neurons. 
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Figure 7  CB1 receptor activation induced by MVs drives to intracellular signaling pathway activation  
 
MV administration induced an increase in P-ERK levels. This effect is prevented by co-
administration of the CB1 receptor antagonist SR141716A (1 μM)  (normalized data; N =3); 
Kruskal–Wallis ANOVA, P = 0.002, Dunn’s tes t for comparison among groups, P < 0.05
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eCBs are carried on the surface of microglial 
MVs 
We can speculate that CB1 receptor activation can happen only if (or when) 
eCBs are exposed on the surface of MV. We’ve already provided evidence of the 
fact that MVs and neurons can interact by surface-to-surface contact in Antonucci 
et al, 2012. Here we show a representative confocal image, complete with x-y 
projections, of neurons exposed to farnesyl-GFP–positive MVs (f-GFP-MVs) for 3 
h and repeatedly washed, where MVs appear to bind neuronal surface (SNAP25-
positive) without undergoing internalization (Figure 8A). Farnesyl-GFP labels MV 
membranes. 
To verify eCB localization on MVs, AEA detection was necessary. Since no 
good antibody against AEA is available at the moment, we took advantage of a tool 
specifically designed for AEA visualization: a biotinylated analog  of AEA, labelled 
with Cy3-streptavidin. As shown in Figure 8B, biotin-AEA localized on MVs 
surface (calcein-positive), indicating that AEA has affinity for MV membrane. 
Control MVs, incubated with Cy3-streptavidin but not with biotin-AEA, didn’t 
show any reactivity for Cy3-streptavidin (Figure 8B), ruling out the possibility that 
the reactivity we saw in biotin-AEA–treated samples were due to artifacts, 
generated by streptavidin molecule aggregation and interaction with MV plasma 
membrane.  
Finally, we showed that MV membranes, obtained from MVs broken by 
hipo-osmotic stress and depleted of their luminal cargo, maintained their capabili ty 
to depress mIPSC frequency (Figure 8C), supporting the idea of a surface 
localization for AEA on MVs.  
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Figure 8   AEA localizes on the membrane of microglial MVs 
 
A. Confocal images of cultured neurons after a 3h incubation with fGFP labelled MVs (in 
green) and several washes. MVs derived from primary glia transfected with fGFP and 
corresponded to the 10,000g pellet; after fixing, neuronal surface was imaged using an 
antibody against SNAP25 (in red), while DAPI dye (in blue) labels cell nuclei. The binding 
of MVs with the membrane is more clearly shown in  the x-y projections    
B. Confocal images of MVs produced by calcein loaded microglia (in green), incubated with 
biotin-AEA (5 μM) and Cy3-streptavidin (in red). Biotin-AEA colocalizes with MVs 
surface showing an heterogeneous distribution pattern. No immunoreactivity for Cy3-
streptavidin was detectable on MV membrane when Cy3-streptavidin alone was 
administrated (control).  
C. Effect of MVs broken by hipo-osmotic stress and emptied of their cargo on mIPSC 
frequency (normalized data; N = 3). Kruskal–Wallis ANOVA, P = 0.003, followed by 
Dunn’s test for comparison among groups, P < 0.05  
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Microglial MVs generate excitation-
inhibition unbalance in the brain 
In our previous publication, we reported that microglial MVs enhance 
glutamate release probability from hippocampal excitatory terminals through 
stimulation of sphingolipid metabolism in neurons (Antonucci et al, 2012). Hence, 
microglial MVs are responsible for opposite but synergic effects on excitatory and 
inhibitory synapses, enhancing excitatory transmission and depressing inhibitory 
transmission, thus generating an excitation-inhibition unbalance in the brain.  
In order to investigate whether there is a cross -relation between the two 
pathways activated by MVs (i.e. sphingolipid cascade and CB1 receptor), we 
performed electrophysiological experiments to evaluate: i) MV effects on 
excitatory synapses when CB1 receptors are antagonized; ii) MV effects on 
inhibitory synapses under blockade of the sphingolipid cascade. In both cases MV 
effects were not perturbed. Indeed, MVs maintained their capability to enhance 
mEPSC frequency when co-administrated with the CB1 receptor antagonist 
SR141716A (1 μM) (Figure 9 A-B), demonstrating that MVs directly potentiate 
excitatory transmission and that this action is not dependent on MV-induced 
depression of inhibitory tone. SR141716A (1 μM) alone has no effect on mEPSC 
frequency (N = 3; normalized values: Ctrl = 1.000±0.107, n = 18; SR141716A-
treated = 1.151±0.151, n = 13 cells; Student’s t-test, P = 0.407).   
On the other hand, MV-mediated enhancement of mIPSC frequency was not 
perturbed by the presence of the sphingolipid cascade inhibitor N-
oleoylethanolamine (OEA, 37.5 μM) (Figure 9 C). OEA alone was ineffective on 
mIPSC frequency (N = 3; normalized values: Ctrl = 1.000 ±0.117, n = 22 cells; 
OEA-treated = 1.186±0.173, n = 19 cells; Mann–Whitney Rank-sum test, P = 
0.539). Incidentally, we must say that OEA is an endogenous peroxisome 
proliferator-activated receptor and GPR119 agonist, which acts independently of 
CB1 receptors (Hansen, 2010). 
Taken together these data indicate that MVs are able to deliver different 
signals depending on the glutamatergic or GABAergic nature of target neurons.   
 
 
 
 
- 56 - 
 
 
 
 
 
Figure 9   Microglial MVs act on excitatory and inhibitory synapses through distinct molecular pathways  
 
A. Representative mEPSC traces of untreated (control) 13-15 DIV hippocampal neurons and 
neurons treated with MVs alone or in co-administration with the CB1 receptor antagonist 
SR141716A (1 μM) 
B. MV effect on mEPSC frequency was preserved in the presence of SR141716A (1 μM) 
(normalized data; N = 4). One-way ANOVA, P = 0.007, followed by Holm-Sidak’s test for 
comparison among groups, P < 0.05, P < 0.01 
C. MV effect on mIPSC in the presence of the sphingolipid cascade inhibitor OEA (37.5 μM) 
(normalized data; N = 5). One-way ANOVA, P = 0.003, followed by Holm–Sidak’s test for 
comparison among groups, P < 0.05, P < 0.01  
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eCBs are very important bioactive molecules in the brain, being involved in 
synaptic plasticity, synaptogenesis and synaptic circuit formation and in several 
brain functions (Benarroch, 2014). However, how they cross cell membranes and 
move in the extracellular space is a challenging and still unsolved issue, become a 
hot topic in eCB research (Maccarrone et al, 2010; Nicolussi and Gertsch, 2015; 
Fowler, 2013). 
Whether eCBs trespass cell membrane through passive diffusion, c arrier-
mediated transport or other mechanisms is still matter of debate ( Maccarrone et al, 
2010; Nicolussi and Gertsch, 2015; Fowler, 2013). Proteins and other structures 
that bind AEA intracellularly have been identified (i.e. FABP -5 and 7, heat-shock 
protein 70, albumin, lipid droplets), while the role of FLAT as intracellular AEA 
transporter cannot be endorsed given current results (Fowler, 2013; Kreitzer and 
Regehr, 2001; Leung et al, 2013). Relative to extracellular transport, AEA could 
likely bind circulating proteins. Lipocalins and albumin are putative extracellular 
carriers (Piomelli, 2003; Stanton et al, 2005). 
On the other hand, my laboratory recently reported how reactive microglia 
release EVs upon ATP stimulation (Bianco et al, 2009; Bianco et al, 2005). EVs are 
an important mechanism of intercellular communication : they shuttle active 
molecules from a donor to a recipient cell or release them in the extracellular 
environment (Cocucci and Meldolesi, 2015; Raposo and Stoorvogel, 2013). EVs 
can contain all kinds of signaling molecules and we demonstrated that a not yet 
identified membrane constituent of microglial MVs increase glutamate release 
probability in cultured hippocampal neurons, acting on sphingolipid cascade 
(Antonucci et al, 2012). Additionally, microglia do produce eCBs and the 
production increases greatly under inflammation (Stella, 2009).    
Hence, we explored the possibility that active eCBs may be released from 
microglial cells in association with EVs and thus signal to neurons.  
 
Here we show that the eCB AEA is enriched in EVs released from microglia 
(both MVs and exosomes) as compared to donor cells, thus providing evidence that 
AEA may be released in association with EVs. We noted that in this study lower 
AEA absolute concentrations in microglial cultures relative to previous studies 
have been detected (Carrier et al, 2004; Walter et al, 2002). We attributed this to 
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the fact that eCBs are labile substances, difficult to be measured, and it’s known 
that the detected levels vary among different experimental conditions. 
Furthermore, our findings indicate that eCBs present in MVs are 
biologically active on neurons. In fact, eCB-storing MVs are able to activate 
presynaptic CB1 receptors and trigger their downstream signaling,  thus inhibiting 
mIPSC frequency and activating ERK pathway in GABAergic neurons in culture  
(Figure XII). 
 
 
 
 
Figure XII  Microglial MV effects on inhibitory synapses. Microglial cells release eCBs in association with 
EVs. Microglial MVs are able to activate CB1 receptors on inhibitory presynaptic terminals thus inhibiting 
GABA release and activating ERK pathway. 
 
 
It’s known that microglial cells release active molecules which affect 
neuronal functions and regulate network formation (Zhan et al, 2014; 
Schlegelmilch et al, 2011; Kettenmann et al, 2013). We can speculate that 
microglia, through the release of eCB-carrying EVs, can regulate axon guidance 
and circuit formation of GABAergic neurons in the developing brain.  
Notably, microglial EVs contain other molecules important for brain 
development, such as the morphogen Wnt3a (Hooper et al, 2012), a hydrophobic 
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lipid-modified protein (Zecca et al, 1996). Thus we can hypothesize that microglia 
can secrete different hydrophobic molecules, involved in brain circuit constitution, 
through EVs. Further experiments will be necessary to explore this possibility.  
eCB receptors and hippocampal neurons in cultures 
Our findings show that CB1 receptors are expressed on GABAergic rather 
than glutamatergic hippocampal neurons in culture and CB1 receptor agonist effects 
on spontaneous synaptic activity reflect their expression pattern. These results 
appear in line with immunocytochemical and electrophysiological evidence 
reported in literature. 
Indeed, although Sullivan and colleagues showed a significant increase in 
mEPSC frequency in hippocampal cultures after WIN55-212,2 administration 
(Sullivan, 1999), this effect was very small, not comparable to that reported on 
mIPSC frequency (Irving et al, 2000). Actual CB1 receptor-mediated effects on 
hippocampal excitatory synapses remain in fact controversial, since data reported 
in literature are very heterogeneous, “ranging from no effect to complete 
obliteration of synaptic response” (Bajo et al, 2009). Possible difference between 
the results can be due to different experimental conditions.  
 
Some claim that usual techniques are not sensitive enough to detect the 
probably very low levels of CB1 receptors present on adult glutamatergic terminals 
in the hippocampus (Irving et al, 2000). And, effectively, in situ hybridization 
experiments for mRNA detection, performed by Marsicano and Lutz, report the 
existence, at much lower levels than in inhibitory cells, of CB 1 receptor mRNAs in 
non-GABAergic neurons which, according to them, must be excitatory 
glutamatergic cells (Marsicano and Lutz, 1999).  
On the other hand, Yasuda and colleagues have recently reported how in the 
hippocampus excitatory synaptic plasticity mediated by CB1 receptors is 
prerogative of immature synapses rather than of adult ones. In fact, according to 
them, CB1 receptors can actually be expressed at glutamatergic synapses but they 
are detectable only at early development stages (Yasuda et al, 2008; Benarroch, 
2014). 
 
We didn’t explored the possibility that vesicular eCBs may activate also 
CB2 receptors. This was beyond the aim of this study, which was primarily to 
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evaluate whether eCBs were present in MVs, using patch-clamping of neurons 
expressing CB1 receptors as an eCB readout. CB2 receptors are primarily express in 
immune cells, while their presence in neurons is still highly controversial 
(Malfitano et al, 2014). 
eCBs are released on the surface of EVs 
The lack of appropriate antibodies prevented us to directly detect eCBs on 
microglial MV surface. However our findings indicate that eCBs are carried on the 
membrane of MVs, since MV membrane fraction maintains the capability to 
activate pre-synaptic CB1 receptors. Moreover, in order to activate eCB receptors, 
eCBs must be exposed on the outer leaflet of MV membranes. Supporting this 
theory, our confocal microscopy evidence shows that MVs make stable contact with 
neuronal surface and that the biotinylated analog of AEA has affinity for MV outer 
membrane. Further experiments will be necessary to describe more precisely eCB 
localization on MVs and to characterize the mechanisms of vesicular eCB 
interaction with CB1 receptors. Yet, cholesterol may be a good candidate as 
mediator of a possible AEA translocation through EV membrane bilayer (Fowler, 
2013).  
Microglial MVs alter excitation-inhibition balance in the brain 
A proof-of-principle of the fact that microglia MVs increase excitation-
inhibition balance in the brain was provided by our previous in vivo 
electrophysiological evidence after injection of MVs in the rat visual cortex 
(Antonucci et al, 2012). Accordingly to in vivo results, in vitro we found that MVs 
are able to promote excitatory transmission on one hand (Antonucci et al, 2012) 
and to depress inhibitory transmission on the other (Gabrielli et al, 2015; the 
present study) (Figure XIII). 
These effects could be detrimental: MV-mediated potentiation of excitatory 
transmission may be pathological, participating to excitotoxicity phenomena which 
occur in neuroinflammatory diseases characterized by microglia activation (e.g. 
multiple sclerosis) (Centonze et al, 2009; Centonze et al, 2010) . Indeed, it’s known 
from literature that microglial cells secrete mediators able to modulate excitatory 
and inhibitory transmission in the brain under inflammatory conditions (e.g. TNFα; 
Centonze et al, 2009; Centonze et al, 2010; Kettenmann et al, 2011; Kettenmann et 
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al, 2013) and that this may drive to excessive stimulation of neurotransmission and 
excitotoxic damage: the so called glutamate excitotoxicity. 
 
This hypothesis would be in line with the capability of MVs to propagate 
inflammation in multiple sclerosis patients (Verderio et al, 2012). In addition, MV 
release is stimulated by P2X7 receptor activation (Bianco et al,  2005), which 
responds to high extracellular ATP concentrations (Farber and Kettenmann, 2006; 
Lalo et al, 2011). High ATP concentrations represent a typical danger signal 
(Davalos et al, 2005; Fiebich et al, 2014), and P2X7 activation is usually connected 
to damage, neurodegeneration and inflammation (Färber and Kettenmann, 2006; 
Lalo et al, 2011; Abbracchio et al, 2008) . 
 
On the other hand, we cannot exclude that MV effects on synaptic activity 
may have a protective function, representing a homeostatic mechanism devoted to 
the restoration of correct network excitability in case of a deficit in synaptic 
transmission. In this case, microglia would sense the deficit in neuronal activity, 
thanks to their mobile processes, and react to this releasing MVs to mediate an 
overall increase of excitatory firing. This would be in line with the fact MVs do not 
seem to cause any toxic effect on neurons (authors’ observations). Counter, Jimok 
Kim and Bradley E. Alger recently reported that the homeostatic response to 
chronic inactivity is a decrease, instead of an increase, in eCB tone, responsible for 
specifically straightening the subpopulation of CB1-expressing interneurons present 
in hippocampus (Kim and Alger, 2010).  
 
Further experiments will be necessary to clarify whether the release of MVs 
from microglia has to be considered as part of a pathological or physiological 
process.  
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Remarkably, the amount of MVs employed was that produced by a double 
number of microglial cells compared to neurons (microglia-to-neurons ratio 2:1): 
i.e. a concentration close to that present in the rodent brain, where microglia are 
about as common as neurons. However, more work will be necessary to define 
unequivocally whether this concentration is actually typical for physiological 
conditions or it is reached only in a pathological status, when activated microglia 
proliferate (Graeber and Streit, 2010) and release higher amounts of MVs (Bianco 
et al, 2009). 
Microglial MVs act on excitatory and inhibitory synapses 
through distinct pathways 
The evidence collected so far corroborates the notion that microglial MVs 
represent an important mechanism of cell-to-cell communication. Furthermore this 
study shows that MVs are able to deliver distinct messages and activate distinct 
signaling pathways depending on the GABAergic or glutamatergic nature of 
recipient neurons (Figure XIII). They inhibit GABA release through CB1 receptor 
activation specifically on inhibitory neurons, and they directly potentiate glutamate 
release through stimulation of the sphingolipid cascade in excitatory neurons. This 
is indicated by the cross-check experiments with the sphingolipid cascade inhibitor 
and the CB1 receptor antagonist on inhibitory and excitatory synapses respectively . 
Indeed, pharmacological blockade of sphingolipid metabolism doesn’t prevent the 
down-regulation of inhibitory transmission evoked by MVs, while MV-mediated 
effects on excitatory transmission are maintained upon inhibition of CB1 receptors. 
 
The sphingolipid Sphingosine accounts for MV-mediated action on 
excitatory synapses, as previously demonstrated by us (Antonucci et al, 2012). 
Besides, a recent paper reported that the sphingolipid sphingosine -1-phosphate 
(S1P) is an antagonist of CB1 receptors (Selley et al, 2013). Thus, it is possible that 
the increased sphingolipid production, that we registered after MV treatment 
(Antonucci et al, 2012), may not only directly induce the potentiation of excitatory 
wiring (through Sphingosine) but also mask an hypothetical vesicular eCB-
mediated inhibition of glutamate release (through S1P). 
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EV isolation 
EVs are mostly isolated through differential centrifugation, although other 
protocols are sometimes used. A standardize EV isolation and purification protocol 
is still lacking and the extraction of exosomes and MVs appears a complex issue by 
now (Cocucci and Meldolesi, 2015; Raposo and Stoorvogel, 2013). Consequently, 
it’s very important to characterize the obtained exosome- or MV-enriched fractions 
using multiple approaches, by taking advantage of different techniques such as 
immunoblotting, imaging, electron microscopy and the more innovative 
Nanoparticle Tracking Analysis (Nanosight
®
) or Tunable Resistive Pulse Sensing 
(Izon qNANO
®
) (Raposo and Stoorvogel, 2013; Yanez-Mo et al, 2015). 
Here we provided a deep characterization of EVs, MV- and exosome-
enriched fractions used in our experiments, isolated through differential 
centrifugation 10,000g/100,000g after clearing by cell debris (see “Materials and 
Methods”). And we integrated the characterization carried out previously  by the 
laboratory (Bianco et al, 2009), using different and updated methodologies.   
 
CONCLUSIONS 
In conclusion, our study demonstrates that: 
 eCB AEA is enriched in EVs, both MVs and exosomes, produced by 
microglia; 
 vesicular eCBs are biologically active, as MVs activate CB 1 and its 
downstream signaling and inhibit mIPSC frequency; 
 MVs are able to deliver distinct signals depending on the glutamatergic or 
GABAergic nature of the recipient neuron. 
 
In addition, these data suggest that microglia-derived MVs may affect 
excitatory-inhibitory balance in the adult nervous system. In fact, MVs increase 
excitatory transmission and directly downregulate inhibitory transmission.   
More broadly, results from these experiments identify EVs as an ideal 
vehicle for the transport of hydrophobic signaling molecules which, like eCBs, 
move across the nervous system to exert their biological activity.   
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IMPORTANT NOTES 
This thesis cites the following article, of which I’m the first author:  
Active endocannabinoids are secreted on extracellular membrane 
vesicles 
Gabrielli M, Battista N, Riganti L, Prada I, Antonucci F, Cantone L, Matteoli M, Maccarrone 
M, Verderio C. 
EMBO Rep. 2015 Feb;16(2):213-20. doi: 10.15252/embr.201439668. Epub 2015 Jan 7. 
PMID: 25568329 
© 2015 The Authors 
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Animals 
All the experimental procedures involving animals followed the guidelines 
established by the European Legislation (Directive 2010/63/EU) and the Italian 
Legislation (L.D. no 26/2014). All efforts were made to minimize the number of 
animals used and their suffering. 
Cell cultures 
Glial cell cultures 
Primary glial cell cultures were established from P2 Sprague Dawley rat s 
(Charles River Italia) as previously described in (Bianco et al, 2005). Briefly, 
cortex and hippocampi were extracted from pups and subjected to enzymatic 
digestion with 0.25% Trypsin (Gibco) in the presence of 0.5 g/L DNAsi (Sigma -
Aldrich) (15 min at 37°C, twice) in an HBSS-based solution composed of 10% 
HBSS-10X, 10 mM HEPES (pH 7.3), 1% antibiotics (Pen/Strep, Gibco) in dH 20. 
HBSS solution ensures pH stability and sample preservation. In order to remove 
not-dissociated tissue, the supernatant obtained from digestion was collected and 
filtered through a nytex membrane (Millipore) and cells were subsequently 
pelleted. The pellet was dissociated and cells were plated in 75 cm
2
 flasks pre-
treated with poly-L-lysine (10 μg/ml, Sigma-Aldrich). Glial cells were maintained 
in standard conditions (37°C, 5% CO2), in medium containing MEM (Gibco), 20% 
FBS (Fetal Bovine Serum, Gibco), 5.5 g/L glucose (Sigma-Aldrich) and 1% 
antibiotics (Pen/Strep, Gibco). 
 
Primary microglial cultures were obtained and maintained as reported in 
Bianco et al, 2005.  Mixed glial cultures have were shaken for 30 min on orbital 
shaker, in order to detach microglial cells often settled on the layer of astrocytes. 
The supernatant containing microglial cells was collected and pelleted. Microglial 
cells were plated at a density of ~90 cells/mm
2
 in tissue culture dishes pre-treated 
with Poly-DL-ornithine hydrobromide (50 mg/L, Sigma-Aldrich) and maintained in 
glial cultured medium (described above) supplemented with GM-CSF (Granulocyte 
macrophage colony-stimulating factor) supplement. GM-CFS supplement was 
obtained from X-63 cell lines transfected with a GM-CSF plasmid. Cells were 
cultured in standard condition (37°C, 5% CO 2). 
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N9 is an immortalized murine microglial cell line. N9 cells were maintained 
in IMDM medium (Gibco) with 10% FBS (Gibco), 1% L-glutamine (Gibco) and 1% 
antibiotics (Pen/Strep, Gibco) in standard culture condition (37°C, 5% CO2). 
Primary cultures of hippocampal neurons 
Primary cultures of hippocampal neurons were established from E18 
Sprague Dawley rat embryos, as previously described in Bartlett and Banker, 1984. 
Briefly, hippocampi surgically removed from E18 embryos were subjected to 
enzymatic digestion with 0.25% Trypsin (15 min at 37°C) and then to mechanic 
dissociation. During the whole procedure tissues were kept in an HBSS-based 
solution (see above). Cells were plated at a density of ~400 cells/mm
2
 on 24 mm 
glass coverslips pre-treated with poly-L-lysine (1 mg/ml, Sigma Aldrich). Neuronal 
cultures were maintained in standard culture condition (37°C, 5% CO2) in a 
medium with Neurobasal Medium (Gibco), 2% B27 supplement (Invitrogen), 0.5 
mM L-glutamine (Gibco), 12 μM glutamate (Sigma-Aldrich) and 1% antibiotics 
(Pen/Strep, Gibco). After 3 days in vitro (DIV) the medium was partially replaced 
with glutamate-free fresh medium. 
Isolation of MVs, exosomes and mixed EV population 
MVs, exosomes and mixed EV population were isolated from N9 cultures at 
80% confluence or 1-2 DIV primary microglial cultures (plated at a density of 
1x10
6
 cells per ø 60 mm culture dish; ~90 cells/mm
2
). After washing twice with 
PBS (Phosphate Buffer Saline) and once with KRH (Krebs-Ringer’s HEPES 
solution; 125 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4, 1.2 mM KH2PO, 25 mM 
HEPES/NaOH, 6 mM D-glucose and 2 mM CaCl , pH 7.4), microglia or N9 cells 
were incubated with 1 mM ATP in KRH for 30 min/1 h, to stimulate MVs release. 
The EV-containing supernatant was collected and subjected to a double 
centrifugation at 300g for 10 min at 4°C (ALC 4227 R centrifuge, rotor ALC 5690) 
to clear it from cells and debris. MV- and exosome-enriched fractions were then 
separated by differential centrifugation: MV-enriched pellet was obtained through a 
10,000g x 30 min centrifugation at 4°C (VWR CT15FE centrifuge, rotor Hitachi 
T15A61 or Beckman Optima L-90K Ultracentrifuge, rotor SW41Ti); the residual 
supernatant were subsequently centrifuged at 100,000g for 1h at 4°C (Beckman 
Optima L-90K Ultracentrifuge, rotor SW41Ti) to obtain an exosome-enriched 
- 71 - 
 
pellet. Otherwise, to obtain a mixed EVs population, the supernatant was 
centrifuged at 100,000g immediately after 300g pre-clearing.  
To perform electrophysiological recordings, nanoparticle tracking analysis 
(Nanosight) and fluorescent microscopy experiments, the pellets of vesicles were 
resuspended and used immediately after isolation. For mass spectrometry analysis, 
the dry pellets were stored at -80°C. While for western blots the pellets were 
resuspended in SDS sample buffer, as described below.  
Nanoparticle tracking analysis (Nanosight) 
Vesicles present in MV- and exosome-enriched pellets were analyzed for 
particle size distribution and concentration by Nanoparticle Tracking Analysis. 
Nanoparticle tracking is an innovative system for the visualization and analysis of 
particles in liquids: particles are tracked by video one-by-one simultaneously; the 
size of each particle is then evaluated by a software from their Brownian motion; 
particle concentration can be directly estimated too.  
For our experiments, a Nanosight LM10-HS system, complemented with an 
EMCDD camera (Hamamatsu Photonics) and a 405 nm laser was used. Video 
recording and analysis were performed using NTA-software (version 2.3): camera 
shutter speed was 20.01 ms and camera gain 350, while minimal expected particle 
size, minimum track length and blur setting were all set to automatic. MV and 
exosome pellets were resuspended in 0,1µm-filtered sterile KRH (400 μl) and 5 x 
30 sec recordings were performed for each sample. 0,1µm-filtered sterile KRH was 
analyzed and no particle was detected.  All measurements were performed at RT 
(25-28°C). 
Bicinchonic acid (BCA) assay 
Protein content of EVs and donor cells was assessed by bicinchoninic acid 
(BCA) assay, using Micro BCA protein assay kit and BCA respectively (Thermo 
Fischer Scientific). In BCA method, BCA molecules chelate cuprous ion Cu
+1
, 
formed from Cu
2+
 reduction by proteins in alkaline environment. This chelation 
generates a purple-colored reaction product which has a strong absorbance at 562 
nm, proportional to protein concentration in the sample.    
Sample absorbance wes read through a spectrophotometer (Victor
2
 - 1420 
multilabel counter, Wallac) set to 550 nm. 
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Western blot analysis 
MV and exosomes pellets were resuspended in 1X Sample Buffer (from 5X 
solution: 15% SDS, 0.575 M Sucrose, 0.325 M TrisHCl, 0.5% β-mercaptoethanol, 
pH 6.8). Cells were scraped and collected in Solubilization Buffer (290 mM 
Sucrose, 1% SDS, 62.5 mM Tris) complemented with protease inhibitors and 
phosphatase inhibitors (1:1000); then Sample Buffer was added. Samples were first 
boiled at 100°C for 5-10 min, in order to denature ate proteins.  Samples 
components were separated according to their molecular weights by SDS-PAGE 
electrophoresis (in reducing condition) and then transferred on a nicrocellulose 
membrane. After 1h blocking with 5% non-fat dry milk in TBS (Tris-buffered 
saline) with 0.1% Tween20 at RT, we incubated the membrane with primary 
antibodies directed against the proteins of interest, diluted in 5% non -fat milk, 
TBS, 0.1% Tween20. The following primary antibodies were used: mouse anti-
Tsg101 (1:500; Abcam), rabbit anti-alix (1:500; Covalab), mouse anti-flotillin 
(1:1000; BD Transduction), mouse anti-SP1 (1:5000; Upstate), rabbit anti-TOM-20 
(1:500; Santa Cruz Biotechnology), rabbit anti-adypophilin (1:200; Santa Cruz 
Biotechnology), mouse anti-GS28 (1:1000; BD Transduction), rabbit anti-ERK 1/2 
and anti-P-ERK 1/2 T202/Y204 (1:1000; Cell Signalling). After washing with TBS 
0.1% Tween20 (3 x 10 min), the membranes were incubated with species -specific 
secondary HRP antibodies in 5% non-fat milk, TBS, 0.1% Tween20. After washing 
with TBS 0.1% Tween20 (3 x 10 min), with TBS 0.3% Tween20 (3 x 10 min) and 
with TBS (10 min), immunoreactive bands were detected using ECL kit (Thermo 
Scientific) and quantified using ImageJ software. 
LC-ESI-MS 
Endogenous levels of AEA and 2-AG were detected through LC-ESI-MS.  
In LC-ESI-MS the sample is first separated into analyte(s) (molecule(s) of 
interest) and other sample components by liquid chromatography (LC), then the 
analyte is detected, identified and quantified by mass spectrometry (MS). 
Electrospray ion source (ESI) is an interface connecting the LC, which works with 
liquid samples, with the MS, which needs high vacuum. Thus ESI’s role is to 
convert molecules in the liquid phase into ions in the gas phase , compatible with 
MS system. 
AEA and 2-AG contents were measured in EVs from 50x10
6
 N9 cells and 
from 15x10
6
 primary microglial cells and in donor cells; and in MVs and exosomes 
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from 30 x10
6
 primary microglial cells and in donor cells. Samples were subjected 
to lipid extraction with chloroform/methanol (2:1, v/v), in the presence of d 8-AEA 
and d8-2-AG as internal standards, used to improve the accuracy and reliability of 
the measurement. The organic phase was dried and analyzed by LC-ESI-MS, using 
a Perkin Elmer LC system (Perkin Elmer) associated with a single quadrupole API -
150EX mass spectrometer (Applied Biosystems). Quantitative analysis was 
performed by selected ion recording over the respective sodiated molecular ions, as 
previously reported (Francavilla et al, 2009). 
These experiments were performed in collaboration with Natalia Battista 
(University of Teramo and European Center for Brain Research/IRCCS Santa Lucia 
Foundation) and Mauro Maccarrone (University of Rome and European Center for 
Brain Research/IRCCS Santa Lucia Foundation)  at University of Teramo. 
Immunocytochemistry 
Cells plated at a density of ~400 cells/mm
2
 on 24 mm glass coverslips were 
fixed with 4% paraformaldehyde 4% sucrose for 15-20 min and washed with PBS 
(Phosphate Buffer Saline, Sigma Aldrich). After fixing, samples were then washed 
with low salts (3 x 5 min; 150 mM sodium chloride, 10 mM phosphate buffer pH 
7.4) and high salts solutions (3 x 5 min; 500 mM sodium chloride, 20 mM 
phosphate buffer pH 7.4) and incubated with GSDB/Triton blocking solution (Goat 
Serum Dilution Buffer; containing goat serum, Triton X-100, phosphate buffer and 
sodium cloride) for 30-45 min at RT. For the detection of specific antigens, 
coverslips were incubated with primary antibodies diluted in GSDB/Triton. The 
following primary antibodies were used: rabbit anti -CB1 (1:500; Synaptic System), 
guinea pig anti-vGLUT1 (1:1000; Synaptic System), human anti-GAD (kindly gift 
from Prof M. Solimena, Medical School, TU Dresden). For CB1 receptor detection, 
an anti-CB1 antibody directed against the C-terminus (intracellular) epitope of the 
protein was used, which, according to Hajos et al, 2000, shows a significantly 
higher reactivity on axons. After washing with GSDB/Triton, samples were 
incubated with species-specific fluorochrome-conjugated secondary antibodies: 
Alexa-488, Alexa-555 or Alexa-633 fluorophores (Invitrogen). Coverslips were 
then washed in high salts (3 x 5 min) and low salts solutions (3 x 5 min) and with 5 
mM Phosphate Buffer (1 x 10 min) and mounted on microscope slides using 
Vectashied (Vector Laboratories Incorporated) as mounting medium. Images were 
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acquired with a Leica TCS SPE confocal microscope and processed with ImageJ 
software. 
Visualization of MV-neuron interaction 
Farnesyl-GFP-expressing MVs were isolated from glial cultures transfected 
with pEGFP-F Vector (BD Biosciences Clontech). Cells transfected with pEGFP-F 
Vector express GFP on the cell membrane, thanks to the genetic fusion between the 
fluorescent protein and a farnesylation sequence (which target the plasma 
membrane). (Harvey et al, 2001). Neurons were detected using a mouse anti-SNAP-
25 (SMI 81 1:500; Sternberger) primary antibody and with Goat anti-GFP FITC-
conjugated antibody (Novus Biologicals) Images were acquired with a Leica TCS 
SPE confocal microscope and processed with ImageJ software. 
AEA visualization 
AEA visualization was performed taking advantage of a specifically 
developed tool: a biotinylated AEA (biotin-AEA, Tocris; Fezza et al, 2008). First, 
microglia was loaded with calcein-AM (Sigma-Aldrich), a non-fluorescent cell-
permeant dye, which become fluorescent and cell-impermeant when hydrolyzed by 
intracellular esterases. Then they were stimulated with ATP to produce MVs. MV-
enriched fraction were incubated with 5 M biotin-AEA or maintained in 1 ml 
KRH (control) for 10 min at 37°C. After dilution in KRH (12 ml), MVs were 
pelleted at 10.000g, and re-suspended in KRH (50 l) containing Cy3-streptavidin 
(1:200) for 30 min. Control samples were incubated with Cy3 -streptavidin but not 
with biotin-AEA. MV samples were then diluted in KRH (12 ml) and re-pelletted. 
After resuspension in 100 l KRH, MVs were spotted on a glass coverslip and 
observed using a Leica TCS SP5 confocal microscope. Images were acquired using 
the same microscope and processed with ImageJ software. 
Calcium imaging 
Calcium imaging set-up included: an Axiovert 100 inverted microscope 
(Zeiss), Polychrome V light source (TILL Photonics GmbH) and a CCD Imago -QE 
camera (TILL Photonics GmbH). For the analysis, a TILLvisION 4.01 software was 
used.  
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Hippocampal 14-16 DIV cultured neurons were loaded with 2 mM Fura-
2/AM (Invitrogen) for 30 min in the incubator at 37°C, washed with KRH and 
visualized.  
Fura-2/AM is a ratiometric calcium indicator: it reaches absorption maxima 
at two different excitation wavelengths depending on its conjugated or not 
conjugated state. If Fura-2 is bounded to Ca
++
 ions, it is excited at 340 nm, while if 
it’s unbounded, it is excited  at 380 nm. Emission was acquired at the unitary Fura-2 
emission length of 505 nm at 1 Hz. Acetoxymethyl (AM) ester form make Fura-2 
molecule hydrophobic enough to trespass cell membrane. In this way, the ratio 
between emission after excitation at 340 nm and emission after excitation at 380 
nm, will be a value proportional to Ca
++
 levels inside the cells and normalized on 
dye internalizaion. 340/380 fluorescence ratio (F340/F380) was measured in the 
soma of neurons (in regions of interest). Basal Ca
++
 levels were recorded for at 
least 100 secs before stimulus and traces with basal Ca
++
 levels exceeding normal 
physiologic values were excluded.   
EV and drug treatments 
Treatments for electrophysiological recordings 
Neurons were exposed to MVs in an amount of 1.2 µg/ml for 40-45 min at 
37°C. 1.2 µg/ml is the amount of MVs produced by a double number of microglia 
cells compared to the number of neurons treated. MV pellet were carefully 
resuspended in a specific amount of conditioned medium (400 μl) and the single 
coverslip was incubated. 
The CB1 receptor agonist WIN55,212-2 (Sigma-Aldrich), kindly provided 
by Dr Mariaelvina Sala (University of Milan), was acutely administrated to 
neuronal culture at the active concentration of 1 µM in the electrophysiology 
external solution (see “Electrophysiological recordings”), after previous dilution in 
a solution of saline (0.9% NaCl) and Tween-80 (2%)  (Schulz et al, 2013). The CB1 
receptor antagonist SR141716A (Rimonabant, 1 µM, Tocris) was pre-incubated for 
15 min and then co-incubated together with MVs for 40-45 min in culture medium. 
OEA (37 µM, N-oleoylethanolamide, Sigma-Aldrich) was pre-incubated for 15 min 
and then co-incubated together with MVs for 40-45 min as well, accordingly with 
(Antonucci et al, 2012). 
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Broken MVs were obtained through hypo-osmotic stress by resuspending 
MV-enriched pellet in 7.3 mM Phosphate Buffer at 4°C for 30 min on a rotating 
wheel. MVs broken and depleted of their luminal cargo (thus, MV membrane only) 
were collected through centrifugation at 100,000g for 1h.  
oATP (100 M) blocks ATP-mediated release of MVs (Bianco et al, 2005) 
allowing only constitutive release. Microglia was pre-treated with oATP for 10 min 
and then incubated with both oATP and ATP (1 mM) for 30 min, before standard 
10,000g pellet isolation.    
Treatments for western blot analysis 
Neurons were exposed to an amount of MVs (7 µg/ml). Incubations, which 
lasted for different time periods (specified in the text), were performed in incubator 
at 37°C.  
CB1 receptor antagonist SR141716A (1 µM, Tocris), also called 
Rimonabant, were pre-administrated to neurons for 15 min and then co-
administrated together with MVs. 
Electrophysiological recordings 
Miniature postsynaptic currents were recorded using whole-cell patch-clamp 
technique, in voltage-clamp mode and in the presence of 1 μM tetrodotoxin (TTX, 
Tocris). TTX inhibits sodium channel-mediated action potential generation and 
allows the user to record only spontaneous activity. Each miniature event 
represents the spontaneous release of a single synaptic vesicle. 
Whole-cell recordings were performed at RT (20-25°C) using a MultiClamp 
700A amplifier (Axon Instruments), a 1320A Digidata (Axon Instruments) and the 
software P-Clamp 10 (Molecular Devices), on an inverted Axiovert 200 microscope 
(Zeiss). Signal sampling frequency was always set at 10 kHz, while filtering 
frequency was 4 kHz. Recording pipettes were pulled from patch-clamp 
borosilicate capillary glass (World Precision Instruments) to a tip resistance of 3 –5 
MΩ using a two-stage vertical puller (Narishige).  Series resistance was monitored 
at the beginning and during each recording.  
All the experiments were performed on neurons plated at a density of ~400 
cells/mm
2
 and using KRH with the addition of 1 μM TTX (Tocris) as external 
solution. 
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mIPSC recordings were performed on 16-20 DIV hippocampal neurons, 
setting +10 mV as holding potential and using a Cesium Glucona te internal solution 
(130 mM CsGluc, 8 mM CsCl, 2 mM NaCl, 10 mM HEPES, 4 mM EGTA, 4 mM 
MgATP, 0,3 mM Tris-GTP; pH 7.3, adjusted with CsOH). Cesium ions block 
potassium currents which can occur when recording at positive holding potentials. 
The analysis of mIPSC traces was performed using the electrophysiological 
analysis software Clampfit (Molecular Devices). Each event  was selected manually 
setting the threshold value at 5 pA.  
mEPSC recordings were performed on 13-15 DIV hippocampal neurons, 
setting -70 mV as holding potential and using a Potassium Gluconate internal 
solution (130 mM  KGluc, 10 mM KCl, 1 mM EGTA, 10 mM Hepes, 2 mM MgCl 2, 
4 mM MgATP, 0.3 mM Tris-GTP; pH 7.4, adjusted with KOH), as previously 
described in (Antonucci et al, 2012). The analysis of mEPSC traces was performed 
using MiniAnalysis Program (Synaptosoft Inc.). Each event  was selected manually 
setting the threshold value at 10 pA.  
Event frequency and peak amplitude were taken into account. Event 
frequency (“frequency”) is the number of events in a unit of time and is expressed 
in Hertz (Hz = event/sec); peak amplitude (“amplitude”) is expressed in pA and is 
the maximum amplitude from the baseline reached by each event. Our control 
cultures showed an average mIPSC and mEPSC frequency of ~1,4 Hz and an 
average mIPSC amplitude of ~14 pA. Data shown are normalized values. 
Statistical analysis 
Data are presented as mean ± SEM, unless otherwise stated. ‘n’ indicates 
the number of cells, while ‘N’ indicates the number of independent experiments. 
Statistical analysis were performed using SigmaStat 3.5 (Jandel Scientific, San 
Jose, CA, USA) software. Data were first tested for normal distribution  and 
variance, and the appropriate statistical test was performed accordingly to data 
characteristics (see Figure Legends), i.e. to test the difference between the means 
of two normally distributed independent variables, unpaired t -test was used; to test 
differences among more than two normally distributed independent variables, one-
way ANOVA was used, followed by a specific post -hoc test in an all pairwise 
multiple comparison. Differences were considered significant when P<0.05, 
indicated by a single asterisk; P<0.01 is indicated by two ast erisks and P<0.001 by 
three asterisks. The power of each test was calculated and taken into account.   
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